Dynamic adjustments to neuronal energy supply in response to synaptic activity are critical for neuronal function. Gliial cells known as astrocytes have processes that ensheathe most central synapses and express G-protein-coupled neurotransmitter receptors and transporters that respond to neuronal activity. Astrocytes also release substrates for neuronal oxidative phosphorylation and have processes that terminate on the surface of brain arterioles and can influence vascular smooth muscle tone and local blood flow. Membrane receptor or transporter-mediated effects of glutamate represent a convergence point of astrocyte influence on neuronal bioenergetics. Astrocytic glutamate uptake drives glycolysis and subsequent shuttling of lactate from astrocytes to neurons for oxidative metabolism. Astrocytes also convert synaptically reclaimed glutamate to glutamine, which is returned to neurons for glutamate salvage or oxidation. Finally, astrocytes store brain energy currency in the form of glycogen, which can be mobilized to produce lactate for neuronal oxidative phosphorylation in response to glutamatergic neurotransmission. These mechanisms couple synaptically driven astrocytic responses to glutamate with release of energy substrates back to neurons to match demand with supply. In addition, astrocytes directly influence the tone of penetrating brain arterioles in response to glutamatergic neurotransmission, coordinating dynamic regulation of local blood flow. We will describe the role of astrocytes in neurometabolic and neurovascular coupling in detail and discuss, in turn, how astrocyte dysfunction may contribute to neuronal bioenergetic deficit and neurodegeneration. Understanding the role of astrocytes as a hub for neurometabolic and neurovascular coupling mechanisms is a critical underpinning for therapeutic development in a broad range of neurodegenerative disorders characterized by chronic generalized brain ischemia and brain microvascular dysfunction.

Keywords: astrocytes, brain oxidative metabolism, glutamate-glutamine shuttle, neurovascular coupling, Alzheimer's disease, ischemia, epilepsy

**INTRODUCTION**

The brain receives 10% of cardiac output but consumes 20% of total blood glucose and oxygen during cerebral activity to restore ion gradients after action potential conduction and neurotransmission (Magistretti et al., 1999; Magistretti, 2006). Large metabolic demand requires that brain blood flow remain constant despite variations in blood pressure (autoregulation) and that areas of high neuronal activity have correspondingly high metabolic rate and local blood supply (Magistretti, 2006). Astrocytes are multi-functional regulators of neurometabolic coupling that control uptake and release of neurotransmitters (Anderson and Swanson, 2000), influence local blood supply (Zonta et al., 2003; Mulligan and Macvicar, 2004; Takano et al., 2006; Gordon et al., 2008), and directly supply neurons with substrates for oxidative phosphorylation (Pellerin et al., 1998a).

Several characteristics of astrocytes confer suitability for sensing and satisfying neuronal metabolic needs. Protoplasmic astrocytes are highly organized into nearly unique three-dimensional domains (Oberheim et al., 2006) with limited overlap (Ogata and Kosaka, 2002). This feature places astrocytes non-randomly in virtually all central nervous system (CNS) 3D space, which is an ideal anatomical scenario for cells engaging in regional brain activity monitoring and/or corresponding nutritive distribution. Astrocyte process extensions from the soma define domain extremities and extensively ensheathe central synapses (Ventura and Harris, 1999) producing a synaptic structure referred to as the “tripartite synapse” (Araque et al., 1999; Oberheim et al., 2006), in which astrocyte processes are located in close enough proximity to communicating nerve terminals that they receive neurotransmitter input. Astrocyte processes also envelop parenchymal brain arterioles and capillaries in unique spatial domains, extending terminal structures known as endfeet that are directly in contact with the vascular basal lamina (Simard et al., 2003; Oberheim et al., 2006). Endfeet express surface proteins, such as glucose transporters, for uptake of energy substrates from the endothelium (Kacem et al., 1998), and are capable of releasing transmitters that influence local blood flow (Simard et al., 2003; Zonta et al., 2003; Mulligan and Macvicar, 2004; Metea and Newman, 2006;
Astrocytes are therefore also uniquely positioned for bidirectional communication across the blood-brain barrier, as well as being participants in synaptic transmission. In addition, single hippocampal or cortical astrocytes are in contact with up to 600 dendrites (Halassa et al., 2007) and over 100,000 synapses (Bushong et al., 2002), and extend multiple processes to blood vessels (McCaslin et al., 2011). This provides a single-cell linkage between the locus of neuronal activity and sites that can leverage additional energy supply in an arrangement known as the neurovascular unit. This anatomy provides an astrocyte-mediated communication link for energy substrate transfer between blood supply and synaptic terminals (Tsacopulos and Magistretti, 1996; Simard et al., 2003; Rouach et al., 2008).

Protoplasmic astrocytes also form a functional syncytium, where distal processes are connected by connexin gap junctions permitting diffusion of ions and metabolites between neighboring astrocytes (Giaume and McCarthy, 1996; Scemes et al., 1998). This creates a conduit for intercellular communication and flow of metabolites, but also allows intracellular communication through autacellular junctions between processes of the same cell (Wolf et al., 1998; Rouach et al., 2002). Connexin proteins also form hemichannels, which do not connect to adjacent cells, but allow release of small molecules from the cytoplasm into the extracellular space (Contreras et al., 2002; Rouach et al., 2002; Ye et al., 2003). This network of gap junctions is central to astrocyte function and control of brain metabolism, facilitating communication and movement of molecules within and around astrocyte domains.

Peri-synaptic or vascular astrocyte distributions would not be functionally relevant without mechanisms for receiving input. Astrocytes achieve this by expressing numerous types of neurotransmitter receptors that initiate electrically silent activation of astrocytes by enhancing intracellular 

$\text{Ca}^{2+}$ levels. These broad signaling cover a diverse range of neurotransmitter receptors such as $\text{GABA}_\text{A}$ receptors (Kang et al., 1998; Betler et al., 2004; Meier et al., 2008), acetylcholine muscarinic receptors (Takata et al., 2011; Navarrete et al., 2012), $\alpha$-adrenergic receptors (Duffy and Mavricac, 1995; Bekar et al., 2008), H1 histamine receptors (Shelton and McCarthy, 2000), endocannabinoid receptors (Navarrete and Araque, 2008, 2010), purinergic P2Y receptors binding adenosine nucleotides (Guthrie et al., 1999), and metabotropic glutamate receptors (mGluRs) (Porter and McCarthy, 1996; Perea and Araque, 2007). Many papers implicate mGluR5 as a major activator of astrocyte $\text{Ca}^{2+}$ (Bezzi et al., 1998; Zonta et al., 2003; Takano et al., 2006; Gordon et al., 2008; Liu et al., 2011), however, there is recent work suggesting mGluR5 expression decreases with age and does not stimulate $\text{Ca}^{2+}$ signals in adult cortical and hippocampal astrocytes (Sun et al., 2013). More work on this is required before a consensus can be reached.

$\text{Ca}^{2+}$ elevations may represent the fulcrum of a multi-faceted repertoire of potential astrocyte responses to sensory input. There is broad consensus that increased astrocytic intracellular $\text{Ca}^{2+}$ triggers release of gliotransmitters such as glutamate, ATP, and D-serine (Bezzi et al., 2004; Møthet et al., 2005; Jourdain et al., 2007). Gliotransmitters, in turn, can affect synaptic activity (Parpura et al., 1994; Araque et al., 1999; Panatier et al., 2006; Hennenberger et al., 2010; Sasaki et al., 2011; Fossat et al., 2012), produce constriction or dilation of local blood supply vessels (Zonta et al., 2003; Mulligan and Macvicac, 2004; Takano et al., 2006; Gordon et al., 2008) or have an autocrine effect to amplify $\text{Ca}^{2+}$ signals (Suadicani et al., 2006). Additionally, elevation of $\text{Ca}^{2+}$ in a single astrocyte is capable of initiating a similar response in surrounding astrocytes in a regenerative wave-like fashion. This process is primarily dependent on connexin 43 (Scemes et al., 1998; Blomstrand et al., 1999; Haas et al., 2006; Gosejacob et al., 2011) and release of extracellular gliotransmitters, including ATP (Hassinger et al., 1996; Guthrie et al., 1999) and may mediate fast, long-distance intercellular communication between astrocytes (Scemes and Giaume, 2006). It is important to note that recent data challenge the view that astrocyte $\text{Ca}^{2+}$ modulates neuronal activity (Petravicz et al., 2008; Agulhon et al., 2010; Nedergaard and Verkhratsky, 2012) or even that adult astrocytes express $\text{Ca}^{2+}$-mobilizing metabotropic glutamate receptors shown previously to be critical for synaptic effects of astrocytes (Sun et al., 2013). These findings are fueling debate about the functional roles of astrocytic $\text{Ca}^{2+}$ responses in adult animals in vivo. Finer spatial resolution of astrocytic $\text{Ca}^{2+}$ levels may reveal that local responses are limited to process microdomains and not necessarily the cell soma (Shigetomi et al., 2010, 2012; Di Castro et al., 2011), which could partially explain apparent discrepancies. Regional differences in astrocytic physiology and developmental changes in astrocytic expression of neurotransmitter receptors may also be factors. Systematic attention to animal age, brain regions imaged and spatial resolution of astrocyte $\text{Ca}^{2+}$ imaging in vivo will greatly help resolve these issues.

Architectural organization, neurotransmitter receptor expression, and gliotransmitter release are features enabling astrocytes to be prime regulators of synaptic environment and transmission (Araque et al., 1999; Anderson and Swanson, 2000; Hennenberger and Rusanov, 2010), neurovascular coupling (Zonta et al., 2003; Mulligan and Macvicac, 2004; Takano et al., 2006; Gordon et al., 2008), blood-brain barrier function (Ballabh et al., 2004) and carbon source shuttling to neurons in high demand periods (Pellerin et al., 1998a; Rouach et al., 2008). We will discuss the influence of astrocytes on the synaptic environment and cerebral bioenergetics, including how astrocytes handle glutamate, supply neurons with oxidative energy substrates and store glycogen. Mechanisms by which astrocytes couple glutamnergic neurotransmission with neuronal energy metabolism and blood flow regulation will also be discussed. Finally, we will survey astrocyte dysfunction in brain diseases and injuries, including ischemic stroke, epilepsy, and Alzheimer’s Disease.

**ASTROCYTES CONTROL CEREBRAL GLUTAMATE LEVELS**

Glutamate is quantitatively the dominant excitatory CNS neurotransmitter (Fonnum, 1984). Unregulated synaptic glutamate levels, however, can cause neuronal excitatory cell death in multiple diseases (Dong et al., 2009). Therefore, regulation of
synaptic glutamate is crucial. Under normal conditions, glutamate balance in the neuropil is tightly controlled by astrocytes. Astrocytic processes enveloping glutamatergic synapses express active amino acid transport proteins that are the main route of extracellular glutamate removal (Rothstein et al., 1994; Danbolt, 2001). The primary glutamate transporters are Na\(^+\)/glutamate co-transporters of the SLC gene family, termed excitatory amino acid transporter 1 and 2 (EAAT1 and 2) in human tissue (Shashidharan et al., 1994) or glutamate transporter-1 (GLT-1) and L-glutamate/L-aspartate transporter (GLAST) in rodents (Pines et al., 1992; Storck et al., 1992). These proteins rely on the Na\(^+\) electrochemical gradient, maintained by Na\(^+\)/K\(^+\) ATPase activity, to co-transport 1 glutamate molecule and 3 Na\(^+\) ions. Glutamate uptake is energetically expensive, as ATP is consumed by Na\(^+\)/K\(^+\) ATPases, but with sufficient energy supply, perisynaptic astrocyte processes prevent excitotoxic accumulation of glutamate in the neuropil. A Na\(^+\)-independent, glutamate/cystine antiporter is also expressed by astrocytes but this is considered a secondary mechanism of glutamate uptake as these transporters primarily conduct cystine (Cho and Bannai, 1990).

Neurons may also take up glutamate through EAAT3 (EAAC1 in rodents) (He et al., 2000; Chen and Swanson, 2003), EAAT4 (Furuta et al., 1997; Nagao et al., 1997; Jackson et al., 2001), or EAAT5 (Arriza et al., 1997); however, the expression and localization of these transporters vary throughout the brain. For example, EAAT5 is mainly located in the retina (Arriza et al., 1997) and EAAC1 and EAAT4 are found on extrasynaptic neuronal membranes, particularly in the cerebellum, and are believed to modulate glutamate release and post-synaptic excitation (Tong and Jahr, 1994; Overstreet et al., 1999). EAAT3 also readily takes up cysteine (Chen and Swanson, 2003), which is used for glutathione production, suggesting EAAT3 has a central role in neuronal antioxidant defense (Aoyama et al., 2006).

Once synaptic glutamate enters astrocytes, one-third is used as a substrate for oxidative metabolism (Schousboe et al., 1993; Hertz and Zielke, 2004; Hertz et al., 2007). Glutamate can be converted to \(\alpha\)-ketoglutarate by glutamate dehydrogenase or aspartate aminotransferase to replenish components of the tricarboxylic acid (TCA) cycle (Faff-Michalak and Albrecht, 1993; McKenna et al., 2006a). An additional portion of salvaged glutamate is recycled for neurotransmission through a process known as the glutamate-glutamine shuttle (Figure 1). Glutamate is converted to glutamine by astrocytic glutamine synthase (Schousboe et al., 1993; Hertz and Zielke, 2004; Hertz et al., 2007), which can be converted to \(\alpha\)-ketoglutarate by glutamate dehydrogenase. Glutamine is then converted back to glutamate through an active transport mechanism, which is driven by the electrochemical gradient maintained by Na\(^+\)/K\(^+\) ATPase (Fremeau et al., 2004) for synaptic release (McKenna, 2007). This shuttle process is vital for proper synaptic glutamate release because neurons do not express enzymes for de novo synthesis of glutamate, so neuronal glutamate is entirely derived from astrocyte glutamine or \(\alpha\)-ketoglutarate (Yu et al., 1983; Shank et al., 1985). Astrocytes produce de novo glutamate or glutamine from glucose via pyruvate conversion to oxaloacetate by pyruvate carboxylase (Yu et al., 1983; Hertz, 2011).

The glutamate-glutamine cycle not only drives neurotransmitter recycling, but also influences brain metabolism. Astrocytes metabolize glutamate to TCA cycle intermediates (Schousboe et al., 1993; Hertz and Zielke, 2004; Hertz et al., 2007), which diminishes the glutamate pool, and may drive astrocytic glucose consumption, ATP production and de novo glutamate synthesis (Hertz, 2011). Neurons also utilize glutamine and/or glutamate as energy substrates during glucose deprivation in vitro (Peng et al., 2007) or ischemia in vivo (Pascual et al., 1998). They similarly use glutamine or glutamate to replenish intermediates of the TCA cycle during metabolism of other substrates in vitro (Shokati et al., 2005). These observations suggest that the glutamate-glutamine shuttle impacts neuronal metabolism. Glutamate uptake by cultured astrocytes also correlates with increased glycolysis and lactate production (Pellerin and Magistretti, 1994). This is a separate mechanism of glutamate-driven astrocyte-neuron metabolic coupling that will be discussed below.

**ASTROCYTE LACTATE FUELS NEURONAL METABOLISM**

Synaptic glutamate is a direct signal of neuronal activity and, therefore, of metabolic demand. Astrocytes surveying synaptic activity respond with elevated glucose utilization, glycolysis (Pellerin and Magistretti, 1994; Cholet et al., 2001), and lactate production (Pellerin and Magistretti, 1994; Schurr et al., 1999; Voutsinos-Porche et al., 2003; Caesar et al., 2008). Enhanced astrocytic metabolism is thought to result from intracellular...
extracellular space for metabolism by oxidative phosphorylation. Cells utilize systemically delivered glucose and oxygen from the extracellular space for metabolism by oxidative phosphorylation (Pellerin and Magistretti, 1994; Chatton et al., 2000; Loaiza et al., 2003; Porras et al., 2008). Intercellular Na\(^+\) waves are also generated throughout the astrocyte syncytium, elevating glucose uptake, and metabolism in neighboring astrocytes as well (Bernardinelli et al., 2004; Scemes and Giaume, 2006). Furthermore, K\(^+\) released during neurotransmission is taken up by astrocytes, which stimulates glycolysis and lactate export (Bittner et al., 2011; Ruminot et al., 2011).

Glutamatergic neurotransmission increases both neuronal and astrocytic energy consumption, but the primary neuronal energetic substrate during normal and pathological conditions has been debated. One hypothesis is that neurons and astrocytes utilize systemically delivered glucose and oxygen from the extracellular space for metabolism by oxidative phosphorylation (Chih and Roberts, 2003). The second hypothesis proposes astrocytes convert glucose to lactate in an activity-dependent, glutamate-mediated manner for delivery to neurons (Pellerin and Magistretti, 1994; Pellerin et al., 1998a; Magistretti and Pellerin, 1999). This is known as the astrocyte-neuron lactate shuttle hypothesis (ANLSH) and suggests lactate is more than a potentially damaging final metabolite of anaerobic glycolysis (Figure 2; Kasischke, 2008).

In light of the ANLSH, a large body of literature pertaining to production and neuronal use of lactate has accumulated over the last 20 years. Several points have been made. First, there is a correlation between synaptic activity and extracellular lactate concentrations. At rest, the extracellular space around neurons and astrocytes has a homogenous concentration of lactate and glucose (Simpson et al., 2007; Barros and Deitmer, 2010). Extracellular lactate decreases slightly during short periods of brain activation in vivo (Hu and Wilson, 1997; Mangia et al., 2007), possibly because neurons are utilizing lactate for oxidative metabolism (Kasischke et al., 2004). However, extracellular lactate rapidly rises as neuronal stimulation continues for longer periods (Pritchard et al., 1991; Mangia et al., 2007). Oxygen levels remain unchanged, suggesting brain activation stimulates aerobic glycolysis (Hu and Wilson, 1997). Second, in vitro studies demonstrate that glutamate induces glucose transporter (GLUT1) activity and uptake rates in astrocytes (Loaiza et al., 2003), while inhibiting neuronal glucose transporter activity (Porras et al., 2004). This suggests glutamatergic transmission may increase astrocyte glucose availability and reduce neuronal glucose metabolism. Third, lactate can support neuronal survival. In rodent brain slices, inhibition of lactate transport and glycolysis during exposure to glutamate caused a permanent loss of neuronal function (Schurr et al., 1999), while addition of lactate maintained synaptic activity in the absence of glucose (Schurr et al., 1988; Fowler, 1993; Izumi et al., 1997), preventing neurotoxicity (Schurr et al., 1997; Maus et al., 1999; Cater et al., 2001). Fourth, neurons express protein machinery necessary for lactate metabolism. Lactate metabolism is mediated by lactate dehydrogenase (LDH), which reversibly converts pyruvate to lactate with oxidation of NADH to NAD\(^+\) (Tsacopoulos and Magistretti, 1996). Several different LDH isoforms are located in the brain; LDH1 is the main isoform in neurons, while LDH1 and LDH5 are found in astrocytes (Bittar et al., 1996; Tsacopoulos and Magistretti, 1996). Lactate consumption is favored by neuronal LDH1, which promotes conversion of lactate to pyruvate (Bittar et al., 1996). In contrast, there is evidence that astrocytes favor production of lactate (Walz and Munkerji, 1988; Peng et al., 1994), likely due to the properties of LDH5, which has a higher affinity for pyruvate than lactate (Bittar et al., 1996). Lactate is transported between the intracellular and extracellular spaces by monocarboxylate transporters (MCT). MCT are symporters that transport lactate anions with H\(^+\) (Bittar et al., 1996). In contrast, there is evidence that astrocytes favor production of lactate (Walz and Munkerji, 1988; Peng et al., 1994), likely due to the properties of LDH5, which has a higher affinity for pyruvate than lactate (Bittar et al., 1996). Lactate is transported between the intracellular and extracellular spaces by monocarboxylate transporters (MCT). MCT are symporters that transport lactate anions with H\(^+\), suggesting lactate transport is driven by pH (Schneider et al., 1993; Barros and Deitmer, 2010). The distribution of MCTs in the brain is heterogeneous: MCT1, MCT2, and MCT4 are expressed by astrocytes, while neurons express predominately MCT2 (Broer et al., 1997; Gerhart et al., 1998; Pellerin et al., 1998b; Bergersen et al., 2001; Pierre et al., 2002). MCT2 co-localizes with post-synaptic density proteins in dendritic spines and has the highest affinity for lactate of all MCTs (Bergersen et al., 2001). Together, MCT2 and LDH1 provide neurons with lactate protein machinery ideally suited to remove and metabolize lactate from active synapses. Lastly, a recent study found that an important activator of glycolysis, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (Pfkfb3), is continually degraded in neurons (Herrero-Mendez et al., 2009). This suggests glucose metabolism is shifted toward the pentose phosphate pathway and antioxidant production, and that neurons have a low glycolytic rate, necessitating utilization of lactate for aerobic respiration.
There is also a correlation between changes in neuronal and astrocytic redox states and lactate transport and metabolism that may support the ANLSH (Hirrlinger and Dringen, 2010). During glycolysis, cytosolic NADH is produced and must be oxidized back to NAD\(^+\) in order for glycolysis to continue. NAD\(^+\) is replenished by lactate production or redox shuttle systems (glycerol-3-phosphate and malate-aspartate shuttle, MAS) which transfer reducing equivalents to the mitochondrial electron transport complexes. While the level of involvement of the glycerol-3-phosphate shuttle in neuronal NAD\(^+\) homeostasis is not clear (Cammer and Zimmerman, 1982; Waagepetersen et al., 2001; Nguyen et al., 2003), the MAS is important for regenerating NAD\(^+\) for glutamate neurotransmitter renewal and energy metabolism (Palaiologos et al., 1988; McKenna et al., 2006b). Inhibition of the MAS-elevated cytosolic NADH, disrupting the redox balance and limiting lactate consumption (McKenna et al., 2006b) without affecting glucose metabolism in synaptic terminals (McKenna et al., 1993). Moreover, disruption of the MAS in malate-aspartate carrier (aralar) deletion mice resulted in impaired neuronal development (Gomez-Galan et al., 2012), reduced dopamine levels (Llorente-Fochl et al., 2013), and hypomyelination (Ramos et al., 2011), indicating this pathway affects neuronal function in a profound way. There is no clear evidence that this is related to lactate metabolism, however.

The role of the malate-aspartate shuttle in astrocytes is currently debated. Several groups show that astrocytes express low levels of aralar (Ramos et al., 2003; Berkich et al., 2007), which limits MAS activity and requires elevated lactate production to replenish cytosolic NAD\(^+\) (Schurr, 2006; Lemire et al., 2008). In support, astrocyte lactate-to-pyruvate ratios were unchanged in aralar knockout mice, compared to wild type controls (Pardo et al., 2011). In contrast, a recent paper suggests adult cultured astrocytes express aralar and the MAS could be functional (Li et al., 2012). This makes the importance of MAS in astrocytes difficult to determine at this point. Nevertheless, there is a clear correlation between cytosolic redox states and lactate production in astrocytes. In cultured astrocytes, inhibition of oxidative phosphorylation (which elevates cytosolic NADH) increases lactate production and regenerates NAD\(^+\) (Dringen et al., 1993). High levels of NADH also influence transcription factors, including Clock and NPAS2, which activate LDH1 expression in astrocytes (Rutter et al., 2001), further potentiating lactate production. Again, extracellular lactate increases during longer periods of neuronal stimulation (~10 s), and a corresponding elevation of astrocytic cytosolic NADH concentrations is also observed (Kasischke et al., 2004). This means astrocytes may replenish extracellular lactate pools for shuttling to neurons during prolonged activation (Pellerin et al., 1998a; Magistretti and Pellerin, 1999; Magistretti et al., 1999; Bouzier-Sore et al., 2002).

Mathematical modeling has been used to approximate the flux of energy metabolites between neurons and astrocytes based on known mass balances and enzyme/transporter kinetics, with the goal of linking in vitro, in vivo, and functional imaging results. Several models have recently been presented, but with varying results. One model describes energy substrates (lactate, glucose, pyruvate), oxygen, and NADH concentrations within the neuronal and astrocyte energy compartments, while also considering the subcellular compartments (cytosol and mitochondria) (Aubert et al., 2007), glutamate transport, and astrocyte glycogen (Cloutier et al., 2009). Results from this model support the ANLSH (Aubert et al., 2007; Cloutier et al., 2009) and the flow of lactate from astrocytes to neurons. The second model focuses on glucose and lactate transport between the blood-brain barrier, neurons, and astrocytes and suggests that neurons primarily metabolize glucose and export lactate (Simpson et al., 2007; Mangia et al., 2009). This supports a neuron to astrocyte lactate shuttle hypothesis (NALSH) (Simpson et al., 2007; Mangia et al., 2009). A third model attempts to combine metabolism rates and concentrations from the first model with transporter kinetics and metabolite diffusion equations from the second model and the results also support a neuron to astrocyte lactate shuttle (Dinuzzo et al., 2010). While the outcomes and design of these mathematical models continue to be debated, each model succeeds in raising questions to be addressed by future experiments. Most notably, there is evidence that neurons can utilize lactate as an energy source during periods of activation, but the question remains: do astrocytes produce lactate for neuronal consumption? Clearly, neurons and astrocytes produce and utilize lactate differently based on the expression profiles and properties of LDH and MCT isoforms, but due to experimental limitations of lactate detection, it is not possible to distinguish lactate producers from the cell type that utilizes lactate, or if these roles change depending on region or activity (Barros and Deitmer, 2010). Measurement of radiotracer kinetics in vivo suggest neurons consume lactate during activation (Wyss et al., 2011), and further in vivo studies may elucidate the complex flux of brain metabolites. In particular, experiments involving awake animals may more accurately reflect brain metabolic states, as anesthetics are known to decrease metabolic rates (Alkire et al., 1995, 1997, 1999). It would also be beneficial to directly visualize in vivo glucose and lactate levels (possibly via fluorescent sensors for glucose or lactate) to determine metabolite concentrations in different cell populations in various brain regions during activation (Barros et al., 2013; San Martin et al., 2013).

Astrocyte lactate is not only a potential energy substrate, but also acts as a signaling molecule in other brain bioenergetic processes, including blood flow regulation (discussed in detail later) (Gordon et al., 2008), blood glucose sensing (Lam et al., 2005, 2007), and sodium sensing in the subfornical organ (SFO; Shimizu et al., 2007). Brain lactate is involved in a brain-liver signaling axis. Hypothalamic arcuate nuclei projections to the brainstem signal to vagal hepatic efferents (Schwartz et al., 2000; Grill et al., 2002) to regulate blood glucose levels (Lam et al., 2005) and insulin signaling (Pocai et al., 2005). Elevated blood glucose leads to increased glial glucose uptake (Chari et al., 2011) and lactate production in the rodent hypothalamus (Lam et al., 2005). Lactate is transported into hypothalamic neurons for conversion to pyruvate. This process is required to activate neuronal ATP-sensitive K\(^+\) channels (K\(_\text{ATP}\)) (Lam et al., 2005), and K\(^+\) flux that induces hyperpolarization and reduces firing (Pocai et al., 2005). Resulting hepatic vagal stimulation (Pocai et al., 2005) reduces gluconeogenesis and glycolysis rates (Lam et al., 2005; Pocai et al., 2005), leading to secretion of very-low density lipoprotein (Lam et al., 2007) and reduced expression.
of hepatic enzymes for endogenous glucose production, including glucose-6-phosphatase (Lam et al., 2005; Pocai et al., 2005; Kishore et al., 2011). This provides a lactate-mediated brain-liver negative feedback axis (Lam et al., 2007), which has implications in obesity and hepatic insulin resistance. In particular, hypothalamic glial GLUT1 expression and glucose uptake are decreased during hyperglycemia in rodents in vivo, and this can form the basis of blood glucose dysregulation in diabetes (Chari et al., 2011). Also, intracerebroventricular injection of lactate decreased blood glucose levels in animal models of uncontrolled diabetes and diet-induced insulin resistance, independent of insulin signaling (Chari et al., 2008), which suggests that hypothalamic lactate could be a future therapeutic target.

In the SFO of the brain periventricular region, lactate influences salt intake behavior and blood Na\(^+\) sensing (Shimizu et al., 2007). Glial cells of the SFO express atypical sodium (Na\(_{ATPase}\)) channels (Hiyama et al., 2004), which have a concentration-sensitive, extracellular sodium threshold of 150 mM (Hiyama et al., 2002). SFO glial Na\(_{ATPase}\) channels interact with Na\(^+\)/K\(^+\) ATPase and progressive Na\(^+\) influx upon elevated extracellular Na\(^+\) triggers anaerobic glucose metabolism and lactate production (Shimizu et al., 2007). Lactate and Na\(_{ATPase}\) channels mediate salt-intake behavior, since Na\(_{ATPase}\)-knockout mice continue to ingest salt when dehydrated (Hiyama et al., 2004) and they have reduced SFO lactate concentrations compared to wild type animals (Shimizu et al., 2007). Salt-intake behavior is reduced when glial lactate stimulates inhibitory neurons in the SFO by a MCT-dependent mechanism (Shimizu et al., 2007). This mechanism may also involve inhibition of K\(_{ATP}\) channels by lactate-induced ATP production (Shimizu et al., 2007); however, further experiments are required to determine the involvement of these channels in the pathway. These studies of the role of lactate in glucose and sodium sensing and food intake behaviors indicate an exciting new role for lactate as a signaling molecule to neurons and suggest the importance of lactate in the brain may be underestimated.

**ASTROCYTE GLYCOGEN PRODUCTION FUELS NEURONAL METABOLISM**

Glycogen is the main cellular storage depot of glucose in mammals (Brown and Ransom, 2007). When glucose is in excess of immediate energy requirements, it can be stored as glycogen; glycogen is mobilized to glucose when glucose levels cannot meet energy demands (Brown and Ransom, 2007). Astrocytes are the main glycogen repository in the adult brain (Phelps, 1972; Koizumi, 1974). Astrocytes express both glycogen synthase (GlyS, for glycogen formation) and glycogen phosphorylase (GlyP, for glycogen degradation) (Pellegrini et al., 1996) and glycogen stores are primarily located in regions of high synaptic density, such as gray matter (Phelps, 1972; Sagar et al., 1987). Astrocyte glycogen is critical for maintaining neuronal survival and synaptic activity during hypoglycemia in vitro (Swanson and Choi, 1993) and in vivo in cortex, hippocampus (Suh et al., 2007) and optic nerve (Wender et al., 2000). Similarly, during periods of increased brain activity and local glucose depletion, astrocyte glycogen stores can be rapidly degraded to provide a temporary energy supply (Shulman et al., 2001; Brown et al., 2003, 2005).

Glycogen cycling occurs when astrocytes acquire glucose through the glucose transporter, GLUT1, and rapidly phosphorylate it to glucose 6-phosphate in the first steps of glycolysis, preventing it from leaving the cell (Vannucci et al., 1997). Glucose-6-phosphate can be converted to glycogen through a process catalyzed by GlyS (Figure 2). GlyS exists in both an inactive phosphorylated form and an active dephosphorylated form. Astrocyte glycogen formation is therefore regulated by enzymes that dephosphorylate and activate GlyS, most notably protein phosphatase 1 which acts via the regulatory subunit Protein Targeting to Glycogen (PTG) (Allaman et al., 2000). Expression of PTG is stimulated by numerous molecules such as vasoactive intestinal peptide, norepinephrine, and adenosine, which increase glycogen production (Sorg and Magistretti, 1992; Allaman et al., 2000). Similarly, GlyP can be regulated by phosphorylase kinase, which converts GlyP from its inactive form to its active, phosphorylated form (Brown and Ransom, 2007). GlyP is only expressed in astrocytes, solidifying the specialization of these cells in glycogen utilization. Glycogenolysis results in glucose-6-phosphate, which can be metabolized within astrocytes to lactate (Dringen and Hamprecht, 1993; Tekkok et al., 2005) or free glucose (Ghosh et al., 2005). This suggests astrocyte glycogen-derived substrates can be supplied to other brain cells for oxidative metabolism.

The astrocytic glycogen reservoir is dynamic under normal brain activity and euglycemic conditions (Brown et al., 2005), and is influenced by glutamatergic neurotransmission and uptake. Glutamate triggers glycogenolysis to meet the energy demand of the glutamate-glutamine cycle and Na\(^+\) gradient restoration, in addition to the mechanisms proposed in the ANLSH (Shulman et al., 2001). Glycogenolysis fuels glutamate uptake by enhancing active transport-mediated recovery from the extracellular space, since inhibition of glycogenolysis-elevated extracellular glutamate concentrations (Sickmann et al., 2009; Schousboe et al., 2010). Glycogenolysis also facilitates de novo synthesis of glutamate and glutamine (Sickmann et al., 2005; Gibbs et al., 2006, 2007). Therefore, astrocyte glycogen is important for supporting the energetic needs of glutamatergic neurotransmission.

Recent studies have found glycogen-derived lactate is central to higher cognitive function and memory formation (Gibbs et al., 2006; Newman et al., 2011; Suzuki et al., 2011). In day old chicks, a bead discrimination learning task for memory consolidation was impaired after inhibition of glycogenolysis (Gibbs et al., 2006, 2007) or injection of poorly metabolized D-lactate (which competes with L-lactate for transport) (Gibbs and Hertz, 2008). An in vivo study of rats during an inhibitory avoidance test found learning-induced glycogenolysis and lactate release that was important for long-term memory formation (Suzuki et al., 2011). This was determined by administering inhibitors of glycogen phosphorylation or knocking down expression of MCT1/4 or MCT2, which induced amnesia. Inhibition of glycogen phosphorylation also reduced long-term potentiation (LTP), which was rescued by lactate injection (Suzuki et al., 2011). In another rat study during a spontaneous alternation task to assess spatial working short-term memory, lactate concentrations increased during the task and inhibition of glycogenolysis and lactate transport decreased task success (Newman et al., 2011). These results suggest astrocyte glycogenolysis and lactate transport to neurons.
is required for working memory processing and long-term memory consolidation.

While debate over the primary neuronal energy source will likely continue, it is clear that there is situational activity-dependent regulation of neuronal metabolism by astrocytes involving glycogen cycling, lactate production, and the glutamate-glutamine shuttle. This metabolic coupling of astrocytes and neurons appears to be important for higher cognitive function.

**ASTROCYTES MEDIATE VASOMOTOR RESPONSES BASED ON TISSUE ENERGY DEMAND**

Neuronal activity is tightly coupled to increased local blood flow by neurovascular coupling in a response termed functional hyperemia. Neurovascular coupling is a complex, multi-modal response involving numerous identified signaling pathways and resulting in vasodilation of penetrating arterioles upstream of regions with enhanced activity, and vasoconstriction in regions with abundant substrate supply and lower activity (Devor et al., 2007). The net effect of this response is to enhance glucose and oxygen delivery from blood to meet neuronal and glial energy demands.

Astrocytic spatial architecture permits relay of signals from synapses to penetrating arterioles and capillaries. As part of the multi-faceted response of astrocytes to increased neuronal activity, synaptic neurotransmission triggers elevated intracellular astrocyte Ca\(^{2+}\) through diverse receptor types including GABA\(_B\) receptors (Kang et al., 1998; Bettler et al., 2004; Meier et al., 2008), acetylcholine muscarinic receptors (Takata et al., 2011; Navarrete et al., 2012), α-adrenergic receptors (Duffy and Macvicar, 1995; Bekar et al., 2008), H\(_1\) histamine receptors (Shelton and McCarthy, 2000), endocannabinoid receptors (Navarrete and Araque, 2008, 2010), mGluR\(_5\) (Zonta et al., 2003), and P2Y receptors (Simard et al., 2003). Astrocyte cytosolic Ca\(^{2+}\) elevations (Simard et al., 2003; Zonta et al., 2003; Filosa et al., 2004; Schummers et al., 2008), and inositol-3-phosphate signaling (Straub et al., 2006) are central to neurovascular coupling, stimulating release of vasoactive compounds that dilate or constrict neighboring arterioles (Zonta et al., 2003; Mulligan and Macvicar, 2004; Metea and Newman, 2006; Takano et al., 2006; Gordon et al., 2008). The polarity (i.e., constriction vs. dilation) of these vascular responses involves multiple pathways, discussed in later sections.

**ARACHIDONIC ACID METABOLITES**

Elevated astrocyte cytosolic Ca\(^{2+}\) stimulates activity of phospholipase A\(_2\) (PLA\(_2\)), which hydrolyzes phospholipids to produce arachidonic acid (AA) (Mulligan and Macvicar, 2004; Sun et al., 2005). AA metabolism by several enzymes produces different molecules with variable vascular effects (Figure 3). In brain slices and in vivo, a non-selective cyclooxygenase (COX) or COX-1 inhibitor blocked arteriolar vasodilation after astrocyte Ca\(^{2+}\) stimulations, suggesting AA is metabolized by astrocyte COX-1 to prostaglandin E\(_2\) (PGE\(_2\)) (Zonta et al., 2003; Takano et al., 2006; Gordon et al., 2008). In cortical astrocytes and retinal glia, AA is also metabolized by cytochrome P450 epoxygenase to vasodilator, epoxyeicosatrienoic acids (EETs) (Peng et al., 2002; Metea and Newman, 2006; Liu et al., 2011). Both PGE\(_2\) and EETs open smooth muscle large conductance Ca\(^{2+}\)-sensitive K\(^{+}\) (BK\(_{Ca}\)) channels, triggering hyperpolarization and decreased voltage-gated calcium channel (VGCC) activity (Gebremedhin et al., 1992; Miura and Gutterman, 1998; Higashimori et al., 2010). EETs also indirectly stimulate BK\(_{Ca}\) channels by increasing Ca\(^{2+}\) sparks (Earley et al., 2005). AA metabolism can also cause vasoconstriction. AA can diffuse to smooth muscle cells and be rapidly metabolized by \(ω\)-hydroxylase (another cytochrome P450 enzyme) to produce 20-hydroxyeicosatetraenoic acid (20-HETE) (Mulligan and Macvicar, 2004; Metea and Newman, 2006). 20-HETE causes smooth muscle contraction by inhibiting vascular BK\(_{Ca}\) K\(^{+}\) channels, leading to depolarization and increased Ca\(^{2+}\) entry through VGCC.

At first, these opposing effects of astrocyte AA metabolism on vascular lumen diameter represented a confusing dichotomy in the field. However, the last 5 years have brought some mechanistic clarity showing that the directional control of AA metabolism is finely controlled by metabolic need and nitric oxide (NO). In brain slices and retinal preparations equilibrated with 95−100% oxygen, elevated astrocyte Ca\(^{2+}\) led to vasoconstriction mediated by 20-HETE production (Mulligan and Macvicar, 2004; Gordon et al., 2008; Mishra et al., 2011). However, in brain slices and retinal preparations treated with 20% oxygen, astrocyte Ca\(^{2+}\) elevations caused vasodilation induced by PGE\(_2\) produced from COX-1 activity (Gordon et al., 2008; Mishra et al., 2011). Vasodilation induced by direct astrocyte Ca\(^{2+}\) stimulation in vivo was also mediated by COX-1 (Takano et al., 2006).
Interestingly, part of the mechanism for dictating response directionality appears to be related to lactate production by astrocytes, revealing another critical role for lactate alongside the ANLSH. At 20% oxygen, astrocytes oxidize glucose and produce lactate (Gordon et al., 2008). Astrocyte endfeet express a prostaglandin-lactate transporter that exchanges intracellular lactate for extracellular PGE₂ (Chan et al., 2002). Thus, at 20% oxygen, increased extracellular lactate from astrocyte glycolysis inhibits the prostaglandin-lactate transporter, resulting in elevated extracellular PGE₂ and vasodilation (Gordon et al., 2008). Current consensus suggests astrocytes maintain vascular tone equilibrium (between vasodilation and vasoconstriction) under physiological conditions. When synaptic activity is minimal and oxygen consumption is low, vasoconstriction by 20-HETE is favored because PGE₂ is taken up rapidly through prostaglandin-lactate transporters. During periods of elevated activity, oxygen is depleted and lactate is released from astrocytes, leading to inhibition of the prostaglandin-lactate transporter, more extracellular PGE₂, and vasodilation. This mechanism couples cerebral blood flow regulation and the ANLSH, since astrocyte lactate production may act as a neuronal energy source and signaling molecule to increase blood flow.

While astrocytes may “sense” the oxygen content in their local environment by producing variable lactate levels in vitro (Gordon et al., 2008), the relevance of this mechanism in vivo is not clear. In vivo, oxygen levels may not influence neurovascular coupling like they do in vitro preparations (Lindauer et al., 2010; Mishra et al., 2011). In ex vivo retinal preparations, for example, while incubation with 100% oxygen increases tissue partial pressure of oxygen (pO₂) 16-fold, administering 100% oxygen, increased extracellular lactate from astrocyte glycolysis increases tissue partial pressure of oxygen (pO₂) 20-fold (Mishra et al., 2011). Consequently, retinal neurovascular coupling favors vasodilation under normoxic and hyperoxic conditions in vivo, in contrast to vasoconstriction in vitro under high pO₂. In addition, physiologic cerebral oxygen levels are between 12 and 38 mmHg (Jamieson and Vandenbrenk, 1963; Metzger et al., 1971; O’Hara et al., 2005), suggesting 20-HETE synthesis, which is dependent on binding of molecular oxygen as a cofactor and has a K₉0₂ (Michaelis constant for oxygen) of 60–70 mmHg (Harder et al., 1996), is low in normoxia. Conversely, production of dilatory prostaglandins and EETs, both with K₉₀₂ < 10 mmHg (Harder et al., 1996; Jurank et al., 1999), would be favored at physiologic oxygen. This suggests that the effect of oxygen on the kinetics of AA metabolism may be sufficient to dictate vascular response polarity as observed in vitro; however, the influence of oxygen on responses in vivo may favor dilation and requires further investigation.

The role of NO in functional hyperemia further complicates neurovascular signaling, as NO also modulates AA metabolism (Metea and Newman, 2006). Traditionally, NO has been considered a direct vasodilator, stimulating vascular smooth muscle guanylyl cyclase leading to activation of K⁺ channels and hyperpolarization (Ignarro et al., 1999). However, NO can also inhibit cytochrome P450 enzymes, such as α-hydroxylase, thereby reducing 20-HETE production (Alonso-Galicia et al., 1998, 1999), or cytochrome P450 epoxygenase, mitigating EET production (Udosen et al., 2003). Additionally, NO weakly activates COX-1, while suppressing COX-2 (Fujimoto et al., 2004), which may affect prostaglandin levels. Overall, cerebral vasodilation by NO likely involves both smooth muscle effects and inhibition of 20-HETE production, thereby favoring lumen expansion by prostaglandins and EETs (Sun et al., 2005; Attwell et al., 2010). The opposite effect of NO on AA metabolism, that is inhibition of dilatory metabolism in deference to 20-HETE, may also occur at elevated tissue oxygen in vitro. In retinal preparations maintained in 95% O₂, NO-enhanced constriction produced by glial activation in a manner thought to result from inhibition of EET formation (Metea and Newman, 2006). There is evidence that all NOS isoforms (i.e., nNOS, eNOS, or iNOS) could be involved in 20-HETE modulation. Reduction of vasodilation in vivo by an nNOS inhibitor was reversed by 20-HETE inhibition, suggesting neuronal NO inhibits 20-HETE production in live animals (Liu et al., 2008). Recent evidence from brain slices also indicates that eNOS permits dilation through suppression of 20-HETE synthesis (Stobart et al., 2013). iNOS is more likely to be involved in neurovascular coupling during pathological conditions. Inhibition of iNOS, which is elevated in retinal glia of diabetic animal models, rescued functional hyperemia, possibly by attenuating EET production (Mishra and Newman, 2010).

**POTASSIUM**

Extracellular K⁺ is generated by working neurons and is an effective vasodilator, giving it suitable properties as a neurovascular coupling mediator. Astrocytes have long been known to regulate neuronal membrane potential by removing synaptic K⁺ (Amedee et al., 1997; Kofuji and Newman, 2004), and astrocytes express inwardly rectifying K⁺ channels (BKCa) on vascular endfeet (Filosa et al., 2006). The idea is that astrocytic Ca²⁺-sensitive K⁺ channels (BKCa) on vascular endfeet (Price et al., 2002) as a potential egress route for vasodilatory K⁺. In retinal preparations, it was suggested vasodilation can be triggered via K⁺ efflux through glial endfoot KᵦCa 4.1 channels in response to neurotransmission (Newman et al., 1984; Paulson and Newman, 1987), but studies of KᵦCa 4.1 knockout mice failed to support this idea (Metea et al., 2007). A second mechanism was proposed involving Ca²⁺-dependent astrocyte BKCa channels (Filosa et al., 2006). The idea is that astrocytic Ca²⁺ increases lead to BKCa channel activation, K⁺ release, and smooth muscle relaxation. Moderate astrocytic Ca²⁺ increases indeed triggered BKCa channel-induced dilation of neighboring arterioles, but large astrocyte Ca²⁺ signals produced greater BKCa channel opening, higher astrocyte K⁺ release and vasoconstriction (Filosa et al., 2010). This polarity was dictated by a threshold extracellular K⁺ ([K⁺]ₑ) concentration of 20 mM. Lower than this threshold, conductance of smooth muscle inward rectifying KᵦCa 2.1 K⁺ channels (Bradley et al., 1999) was enhanced, causing hyperpolarization, reduced VGCC activity, and vascular smooth muscle relaxation (Girouard et al., 2010). In contrast, [K⁺]ₑ larger than 20 mM caused smooth muscle depolarization, increasing VGCC conductance, and vasoconstriction (Knut et al., 1996; Knut and Nelson, 1998). This represents another potential mechanism of activity-dependent vasodilation mediated by astrocytes. Moreover, it is another mechanism by which astrocytes...
Carbon monoxide (CO) is produced by heme oxygenase (HO) and can have vasoactive effects. On a cellular level, CO can relax vascular smooth muscle by increasing coupling between smooth muscle BKCa channels and local Ca2+ transients, similar to EET activity (Figure 3; Jaggar et al., 2002; Wu et al., 2002; Xi et al., 2010). CO-mediated vasorelaxation has been observed in peripheral tissues such as liver (Suematsu et al., 1994, 1995) and carotid arteries (Brian et al., 1994), but cerebrovascular results are varied (Brian et al., 1994; Leffler et al., 1999; Ishikawa et al., 2005; Leffler et al., 2006a; Li et al., 2008; Xi et al., 2010, 2011; Morikawa et al., 2012). Brain arteries from rabbits and dogs demonstrated no response to CO (Brian et al., 1994), while arteries from rats and piglets dilated in response to CO (Leffler et al., 1999; Jaggar et al., 2002; Holt et al., 2007; Li et al., 2008; Xi et al., 2010, 2011) or constricted based on CO-induced inhibition of NO dilation pathways (Ishikawa et al., 2005). In piglet studies, glutamate-induced vasodilatation was mediated by CO, as HO inhibitors blocked lumen diameter increases in isolated arteries (Fiumana et al., 2003) and pial arteries in vivo (Leffler et al., 1999; Robinson et al., 2002). Glutamate stimulates endothelium-dependent dilation through CO production from endothelial and smooth muscle cells (Fiumana et al., 2003; Leffler et al., 2003), but also induces CO production in astrocyte endfeet (Leffler et al., 2006b; Parfenova et al., 2012) by Ca2+ and calmodulin-dependent activation of HO (Xi et al., 2011). This astrocyte-specific response can reportedly mediate vasodilation in vivo (Li et al., 2008) indicating CO is another diffusible, vasoactive molecule, released upon astrocytic activation by neurotransmission. Astrocyte CO production and dilation of pial arterioles in vivo can be enhanced by adenosine diphosphate (Kanu and Leffler, 2009), NO (Barkoudah et al., 2004; Leffler et al., 2005a,b), AA and PGE2 (Kanu et al., 2006; Kanu and Leffler, 2011), suggesting an interaction between other dilatory mechanisms and HO activity. A study of adult rat pial arteries in vivo indicated CO-induced cerebral vasoconstriction by inhibiting NO production (Ishikawa et al., 2005), and similar results were observed in piglets, but after prolonged exposure to CO (Knecht et al., 2010; Leffler et al., 2011). Therefore, there may be a polarity to CO-mediated cerebrovascular effects, akin to similar effects seen with AA metabolism and K+ effects.

In summary, astrocytes are not only important for regulating synaptic environments and the supply of energy metabolites to neurons, but they are also central to the regulation of neurovascular coupling by releasing several molecules, including AA metabolites, K+, and CO, in response to synaptic transmission. We are only just beginning to understand how these pathways work in concert to fine-tune regulation of cerebral blood flow.

**ASTROCYTE CONTROL OF CEREBRAL BIOENERGETICS CAN CONTRIBUTE TO DISEASE**

Multiple brain diseases and injuries are associated with aberrant energy metabolism, dysfunctional glutamate cycling by astrocytes, and altered neurovascular coupling. Here, we discuss the major bioenergetic changes and astrocyte dysfunction in Alzheimer’s disease (AD), cerebral ischemia, and epilepsy.

**ALZHEIMER’S DISEASE**

AD is the most common form of dementia, characterized by declining cognitive performance and memory (McKahn et al., 1984). AD pathology is characterized by two types of lesions—amyloid-β (Aβ) plaques, consisting of insoluble, extracellular deposits of Aβ peptide fibrils, and neurofibrillary tangles, composed of intracellular neuronal deposits of hyperphosphorylated and crosslinked tau protein (Merz et al., 1983; Braak and Braak, 1988). Aβ peptides are linked to synaptic dysfunction, activation of microglia and astrocytes, and oxidative stress, but the precise contribution of plaque formation to disease pathogenesis remains controversial (Fuller et al., 2009).

During AD, astrocytes undergo morphological changes, related to proximity of Aβ deposits. In dementia patients and transgenic mice, extensive reactive gliosis appears near Aβ plaques (Rodriguez et al., 2009; Simpson et al., 2010), while astrocytes farther away display dystrophic changes such as decreased complexity, surface area, and volume of cell processes (Senitz et al., 1995; Rodriguez et al., 2009). In many cases, abnormal glial morphology occurs early in disease onset—before amyloid deposition is apparent (Scheff et al., 2007; Rodriguez et al., 2009). Astrocyte dystrophy and reactive astrogliosis may greatly impair astrocytic modulation of synaptic environments and neuronal metabolism, exacerbating AD progression (Fuller et al., 2009; Steele and Robinson, 2012). For example, brain glucose metabolism is diminished in pre-clinical patients (Mosconi et al., 2008) and cerebral glucose uptake in transgenic AD mice (Merlini et al., 2011) and AD patients (Alexander et al., 2002) is significantly reduced, often before Aβ plaques or neurofibrillary tangles are detected (Small et al., 2000). Glycogen-derived lactate is important for memory formation in healthy brain (Gibbs et al., 2006; Newman et al., 2011; Suzuki et al., 2011), and dysfunction of this pathway could contribute to AD pathogenesis. Transgenic AD mice demonstrate decreased brain lactate release during neuronal stimulation (Merlini et al., 2011). In day-old chicks treated with Aβ1–42 peptide, memory consolidation was rescued upon injection of energy substrates, such as acetate, a substrate oxidized specifically by astrocytes (Gibbs et al., 2009). This suggests Aβ may damage astrocyte glycolysis and lactate production, reducing brain metabolism, and impairing memory.

The astrocyte glutamate-glutamine shuttle is also altered during AD. Expression of astrocyte glutamate transporter, EAAT2, is reduced in both transgenic mice and dementia patients.
sugesting astrocytes take up less synaptic glutamate (Li et al., 1997; Masliah et al., 2000; Simpson et al., 2010). Also, both glutamine synthetase activity (Smith et al., 1991) and the concentration of glutamate in cerebrospinal fluid is reduced in AD patients (Csernansky et al., 1996; Jimenez-Jimenez et al., 1998). The confluence of these events results in a dysregulation of glutamate homeostasis and reduced transfer of glutamate to neurons from astrocytes. Neurons in AD brains aberrantly express astrocyte proteins, including the amino acid transporter, EAAT1 (Scott et al., 2002), and glutamine synthetase (Robinson, 2000), possibly in an attempt to normalize glutamate handling and limit excitotoxicity. Neuronal expression of EAAT1 is correlated with neurofibrillary tangle formation (Scott et al., 2002), while glutamine synthetase expression corresponds with plaque formation (Robinson, 2000). Since these enzymes and transporters are critical for glutamate uptake and the glutamate-glutamine shuttle, such dramatic changes in cellular distribution suggest profound astrocyte dysfunction and impaired glutamate handling during AD. In combination with reduced energy metabolism, this may greatly affect neuronal viability and synaptic transmission (Rodriguez et al., 2009).

Impaired vascular reactivity, reduced neurovascular coupling, and diminished resting blood flow are all associated with AD (Mentis et al., 1996; Warkentin and Passant, 1997; Niwa et al., 2000, 2001; Iadecola, 2004), and could be attributed to astrocytes and hemodynamic dysfunction. Cultured astrocytes treated with β4 peptides (1–42 and 25–35) (Abramov et al., 2003; Chow et al., 2010) and in vivo astrocytes from transgenic AD mice exhibit increased frequency of spontaneous, focal intracellular Ca2+ responses not coupled with neuronal activity (Takano et al., 2007; Kuchibhotla et al., 2009). Intercellular Ca2+ waves between astrocytes were also increased in frequency and amplitude in both cultured cells and in vivo (Haughey and Mattson, 2003; Kuchibhotla et al., 2009). Furthermore, Aβ40-peptide accumulates in blood vessel walls (Selkoe and Schenk, 2003; Aghaye et al., 2012) causing endothelial cell deformity, smooth muscle deterioration (Farkas and Luiten, 2001; Merlini et al., 2011), and pericyte toxicity (Wilhelms et al., 2007). This is linked to reduced free NO and vasoconstruction (Thomas et al., 1996; Niwa et al., 2001), and suggests that Aβ accumulation may alter the functional neurovascular unit. The concentration of reactive oxygen species (ROS) also increases in AD transgenic mice (Park et al., 2004), which are known to reduce production of vaso-active molecules, as observed in vitro (Fleming, 2004; Sun et al., 2008). Thus, dysfunctional neurovascular coupling during AD could be caused by altered astrocyte Ca2+ signaling, increased ROS, and gross vascular abnormalities, which change normal intrinsic vascular tone. Astrocyte dysfunction appears to be central to AD initiation and progression, and these cells have now become future therapeutic targets (Fuller et al., 2009).

CEREBRAL ISCHEMIA

During cerebral ischemia, blood flow is restricted by cortical or subcortical occlusion, chronically impaired vascular reactivity or cardiac arrest. Bioenergetic failure results (Hertz, 2008) in a cytotoxic cascade characterized by lactate and proton acidification (Silver et al., 1997) and ROS generation, (Abramov et al., 2007), inhibition of Na+/K+ ATPases, membrane depolarization (Silver et al., 1997) and elevation of extracellular glutamate due to depolarization-induced vesicular release and non-vesicular egress mechanisms. This initiates further membrane depolarization, mitochondrial damage, excitotoxicity, and neuronal death (Schild et al., 2003; Brookes et al., 2004; Nicholls, 2004; Nicholls et al., 2007). Neurons are very sensitive to this chain reaction, while astrocytes are more resistant because they can increase their glycolytic rate (Walz and Mukerji, 1990) or utilize alternate energy substrates for ATP production (Edmond et al., 1987; Hertz, 2003; Hertz and Hertz, 2003). Astrocytes also exploit glutathione stores to limit ROS damage (Juurlink, 1997). In early ischemic stages, astrocytes may help ailing neurons, but prolonged ischemic stress damages astrocytes, which may contribute to neuronal demise (Rossi et al., 2007). As described below, astrocytes affect neuronal survival and metabolism during ischemia through glutamate handling, lactate shunting, and glyogen breakdown, and the transport of metabolites through gap junctions.

During ischemia, neuronal ionic gradients are disrupted by Na+/K+ ATPase inhibition, elevating extracellular glutamate concentrations (Bosley et al., 1983; Goldberg et al., 1988; Hillered et al., 1989). In early stages, astrocytes take up and accumulate intracellular glutamate (Hertz et al., 1998; Voloboueva et al., 2007) in an attempt to balance the extracellular environment, but they continue to shuttle glutamine to neurons, facilitating additional glutamate release (Haberg et al., 2001). Prolonged ischemia disrupts the glutamate-glutamine cycle (Gorovits et al., 1997) due to depleted ATP levels, accumulation of intracellular Na+ and reversal of GLT1 and GLAST to cause facilitated extrusion of glutamate (Anderson and Swanson, 2000; Phillips et al., 2000; Bonde et al., 2003). Furthermore, astrocytes swell and release yet more glutamate through volume-regulated anion channels (Kimelberg et al., 1990). These observations have generated interest in astrocyte glutamate handling as a potential ischemic therapeutic target, since upregulated expression or activity of glutamate transporters or inhibition of volume-regulated anion channels may decrease glutamate excitotoxicity (Rossi et al., 2007).

Progression of neuronal death during ischemia is dependent on availability of energy substrates. Experimental inhibition of lactate transporters (MCTs) during ischemia exacerbates neuronal death and astrocytes display increased conversion of glyco- gen to lactate (via glucose-6-phosphate) during this time (Brown et al., 2005; Tekkok et al., 2005; Suh et al., 2007), suggesting lactate and glyogen are important for maintaining ATP levels and neuronal survival. Lactate can also diffuse through astrocyte gap junctions (Rouach et al., 2008), which remain open during ischemia (Cotrina et al., 1998), facilitating the beneficial flux of lactate within the astrocytic network. As oxygen is depleted, astrocytes appear to be able to sustain neuronal function via anaerobic glycolysis (Rossi et al., 2007). However, there is a fine balance between benefit and injury and eventually lactate builds to concentrations which induce acidosis and cellular damage (Li and Siesjo, 1997). Further experimental testing is required to determine the role of astrocyte glycogen during ischemia. Brain regions with higher than normal glycogen concentrations are more resistant to ischemic damage (Swanson et al., 1989), and increasing glycogen stores in cultured astrocytes reduces neuronal death.
during glucose deprivation (Swanson and Choi, 1993). Protective effects in vivo may also be enhanced by increasing glycogen stores, either through inhibition of GlyP (Suh et al., 2007) or by elevating glycogen synthase activity (Rossi et al., 2007). In cell culture models of ischemia, propagation of signals and metabolites through the glial network is increased through hemichannels (Contreras et al., 2002). This may exacerbate tissue damage as increased hemichannel activity allows Na\(^{+}\) and Ca\(^{2+}\) to diffuse into astrocytes, while glutamate flows out, furthering excitotoxicity (Ye et al., 2003). Also, in astrocyte cultures, glutathione (an important astrocytic antioxidant) is lost over time through hemichannels, limiting ROS protection (Rana and Dringen, 2007). While both hemichannels and gap junctions respond to ischemic signals, they are difficult in vivo therapeutic targets as both are inhibited by the same antagonists, obscuring potential benefits (Rossi et al., 2007).

Reperfusion after ischemia is characterized by reduced blood flow (Leffler et al., 1989) due to disruption of the neurovascular unit via neuronal and vascular ischemic damage (Del Zoppo, 2010). Reduced neurovascular coupling exacerbates ischemic injury, which may increase infarct size. Blood flow is partly reduced because fibrin, activated platelets and/or leukocytes occlude capillaries and venules (Del Zoppo and Mabuchi, 2003). Evidence also suggests that AA metabolite (EETs and 20-HETE) signaling is altered during ischemia, which contributes to decreased blood flow and neurovascular coupling. Recent therapeutic studies have elevated EET levels using inhibitors of soluble epoxide hydrolase (sEH), an enzyme that degrades EETs (Imig and Hammock, 2009). sEH inhibitors are beneficial regardless of administration time, since infarct size is decreased in rodents when the drug is given chronically, shortly after the ischemic insult or during reperfusion (Dorrance et al., 2005; Zhang et al., 2007, 2008; Simpkins et al., 2009). EETs mediate this protection, as inhibition of CYP epoxygenase (the EET synthesis enzyme) prevents sEH benefits (Zhang et al., 2007, 2008). This protective mechanism increases astrocyte survival (Liu and Alkayed, 2005), elevates antiapoptotic factors (Simpkins et al., 2009) and increases neurovascular coupling (Zhang et al., 2007, 2008). Conversely, 20-HETE is elevated during ischemia (Tanaka et al., 2007), and inhibition of 20-HETE production is also neuroprotective in rodent models (Miyata et al., 2005; Poloyac et al., 2006; Tanaka et al., 2007; Dunn et al., 2008; Renic et al., 2009). Reduction of 20-HETE inhibits ROS production (Dunn et al., 2008), limits vasoconstriction and increases blood flow during reperfusion (Miyata et al., 2005; Dunn et al., 2008). Taken together, evidence suggests AA metabolite signaling is dysfunctional during and after cerebral ischemia, whereby EETs are decreased and 20-HETE is elevated. By inhibiting EET degradation and 20-HETE production, functional hyperemia can be restored, and these pathways make promising therapeutic targets.

Focal cerebral ischemia causes altered glutamate handling and lack of energy substrates, which triggers neuronal excitotoxicity, ATP depletion, and ROS production (Hertz, 2008). In early stages of ischemia, astrocytes are less susceptible to damage and may help protect neurons through glutamate uptake, glycogen hydrolysis to lactate for energy, and conduction of protective molecules through gap junctions. However, prolonged ischemia damages the neurovascular unit reducing blood flow and functional hyperemia during reperfusion. Current therapeutic targets are meant to promote astrocyte protection of neurons and help restore proper circulation after stroke.

**EPILEPSY**

Epilepsy is characterized by sudden, temporary synchronization of electrical charges in groups of neurons, which may manifest as seizures. The origins of this disorder are not completely understood (McCormick and Contreras, 2001; Scharfman, 2007), but neuronal hyperexcitability is believed to be caused by disequilibrium between glutamatergic and GABAergic neurotransmission, either by decreased inhibitory (GABA) circuits or excessive glutamatergic release (Dudek et al., 1999; Uhlhaas and Singer, 2006). Dysfunctional astrocyte glutamate-glutamine cycling is also involved (Tian et al., 2005), as astrocyte expression of EAAT2 is diminished in epilepsy patients (Proper et al., 2002; Fotheringham et al., 2007), and knock-down of glutamate transporters [EAAC1 (Sepkuty et al., 2002), GLT-1 (Tanaka et al., 1997), and GLAST (Watase et al., 1998)] in animal models exacerbates neuronal excitability. Also, glutamine synthetase expression is reduced by 40% in astrocytes of epilepsy patients, suggesting that glutamate degradation is greatly diminished (Eid et al., 2004). Therefore, dysfunctional glutamate metabolism in astrocytes could contribute to neuronal synchronization and hyperexcitability.

Ion homeostasis by astrocytes is altered during epilepsy. Particularly, both K\(_{ir}\) currents and aquaporin 4 expression are reduced, (D’Ambrosio, 2004; Eid et al., 2005) and this results in elevated extracellular K\(^{+}\), decreased water homeostasis, and reduced seizure thresholds (Binder and Steinhauser, 2006). Astrocytes also display elevated intracellular Ca\(^{2+}\) signals before and during seizure activity in rodents (Tian et al., 2005; Gomez-Gonzalo et al., 2010, 2011), which are mediated by mGluR and purinergic receptors, and may further exacerbate neuronal activation by triggering gliotransmission (Gomez-Gonzalo et al., 2010). Interestingly, common antiepileptic drugs, such as valproate and phenytoin, reduce astrocytic Ca\(^{2+}\) increases (Tian et al., 2005).

Cerebral bioenergetics are aberrantly regulated in epilepsy, but the precise changes remain unknown. Epilepsy patients display high levels of glucose uptake and hypermetabolism during seizures (Engel et al., 1983), and low levels of glucose uptake and hypometabolism between seizures (Engel et al., 1982). In animal models of epilepsy, astrocyte glycogen accumulates before the onset of seizures for possible conversion to neuronal energy substrates (Bernard-Helary et al., 2000). Glycolytic inhibitors, such as 2-deoxy-D-glucose, have antiepileptic properties (Garriga-Canut et al., 2006), suggesting glycolysis is necessary for neuronal hyperexcitability and synchronization. Also, glucose flux from blood vessels to neurons through astrocytic gap junctions can partially sustain epileptiform activity in brain slices (Rouach et al., 2008). However, connexin knockout mice experience spontaneous interictal bursts and neuronal hyperexcitability, which has been attributed to decreased buffering of extracellular K\(^{+}\) and glutamate (Wallraff et al., 2006; Cloix and Hevor, 2009; Pannasch et al., 2011; Bedner and Steinhauser, 2013). Gap junction trafficking is reportedly altered in epilepsy, possibly permitting elevated...
extracellular K⁺ and glutamate, but how this effects the flow of energy substrates remains unclear (Bedner and Steinhauser, 2013).

Epileptiform activity triggers increased blood flow and deoxygenates hemoglobin (Suh et al., 2006) to meet energy and oxygen demand of active neurons (Kuhl et al., 1980). However, hyperemia may not fully support neurons, since some studies suggest chronic epilepsy may cause ischemic-like tissue damage (Suh et al., 2006). A lag time was identified between astrocyte endfeet Ca²⁺ demand of active neurons (Kuhl et al., 1980). However, hyperemia (Kovacs et al., 2012).

A g y a r e , E ., L e o n a r d , S ., C u r r a n , G ., A b r a m o v , A . Y ., S c o r z i e l l o , A ., a n d
REFERENCES
Abramov, A. Y., Canevari, L., and Duchen, M. R. (2003). Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J. Neurosci. 23, 5088–5095.

Astrocytes may play an important role in epilepsy, but it is unclear if they promote neuronal excitability, or merely sustain seizures and epileptogenesis. Several astrocyte functions are altered during epilepsy including glutamate-glutamine shuttle, ion homeostasis, and movement of metabolites, but the role of astrocytes in functional hyperemia during seizure activity is unknown. In the future, astrocyte glutamate uptake, blood flow control, or metabolism could be targeted to limit neuron excitability.

CONCLUSION
Astrocytes were once considered the “glue” of the brain with little importance to brain function; however, they have emerged as modulators of brain bioenergetics, blood flow, and neuronal survival. Based on spatial orientation, gap junction connections, and complexity, astrocytes are well-situated to influence synaptic environments and function as “gatekeepers” of neuronal metabolism and blood flow. This involves complex, multi-modal mechanism where astrocytes “listen” to synaptic activity and respond through (a) glutamate uptake and recycling via the glutamate-glutamine cycle, (b) increased glycolysis and shutting of metabolites to neurons for oxidative phosphorylation, and (c) elevated Ca²⁺ signaling and release of vasoactive molecules for blood flow control. These responses ensure astrocytes tightly couple neuronal metabolic need with enhanced supply. Furthermore, astrocyte dysfunction may contribute to aberrant neuronal metabolism and neurovascular coupling in disease and injury and these pathways are promising therapeutic targets.

ACKNOWLEDGMENTS
Research is supported by the Canadian Institute of Health Research and Manitoba Health Research Council. Jillian L. Stobart was supported by a doctoral research award from the Canadian Institutes of Health Research.

[45x219]A r a q u e , A ., P a r p u r a , V ., S a n z g i r i , R . P ., a n d H a y d o n , P . G . (1999). Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22, 208–215.

A r r i z a , J . L ., E l i a s o f , S ., K a v a n n a h , M . P ., a n d A m a r a , S . G . (1997). Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc. Natl. Acad. Sci. U.S.A. 94, 4155–4160.

A t t w e l l , D ., B u c h a n , A . M ., C h a r p a k , S ., L a u r i t z e n , M ., M a v c i c a r , B . A ., a n d N e w m a n , E . A . (2010). Glial and neuronal control of brain blood flow. Nature 468, 232–243.

A u b e r t , A ., P e l l i e r i n , L ., M a g i s t r e t t i , P . J ., a n d C o s t a l a t , R . (2007). A coherent neurobiological framework for functional neuroimaging provided by a model integrating compartmentalized energy metabolism. Proc. Natl. Acad. Sci. U.S.A. 104, 4188–4193.

B a l l a b b , P ., B r a u n , A ., a n d N e d e r g a r d , M . (2004). The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1–13.

B a r k o u d a h , E ., J a g g a r , J . H ., a n d L e f f l e r , C . W . (2004). The permissive role of endothelial NO in CO-induced cerebrovascular dilation. Am. J. Physiol. Heart Circ. Physiol. 287, H1459–H1465.

B a r r o s , L . F ., a n d D e i t m e r , J . W . (2010). Glucose and lactate supply to the synapse. Brain Res. Rev. 63, 149–159.

B a r r o s , L . F ., S a n M a r t í n , A ., S o t e l o - H i t c h s e f f l e d , T ., L e r c h u n d i , R ., F e r n á n d e z – M o n c a d a , I ., R u m i n o t , L ., a n d L . (2013). Small is fast: astrocytic glucose and lactate metabolism at cellular resolution. Front. Cell. Neurosci. 7:27. doi: 10.3389/fncel.2013.00027.

B e d n e r , P ., a n d S t e i n h a u s e r , C . (2013). Altered Kir and gap junction channels in temporal lobe epilepsy. Neurochem. Int. doi: 10.1016/j.neuint.2013.01.011. [Epub ahead of print].
Bekar, L. K., He, W., and Nedergaard, M. (2008). Locus coeruleus alpha-adrenergic-mediated activation of cortical astrocytes in vivo. Cereb. Cortex 18, 2789–2795.

Bergersen, L., Waerhaug, O., Helm, J., Thomas, M., Laake, P., Davies, A. J., et al. (2001). A novel postsynaptic density protein: the monocarboxylate transporter MCT2 is co-localized with delta-glutamate receptors in postsynaptic densities of parallel fiber-Purkinje cell synapses. Exp. Brain Res. 136, 523–534.

Berkich, D. A., Ola, M. S., Cole, J., Swett, A. J., Hutson, S. M., and Lanoue, K. F. (2007). Mitochondrial state in mice submitted to methionine sulfoximine. Life Sci. 85, 3367–3377.

Bergers, L., Warhaug, O., Helm, J., Thomas, M., Laake, P., Davies, A. J., et al. (2001). A novel postsynaptic density protein: the monocarboxylate transporter MCT2 is co-localized with delta-glutamate receptors in postsynaptic densities of parallel fiber-Purkinje cell synapses. Exp. Brain Res. 136, 523–534.

Bernard-Helary, K., Lapouible, E., Ardourel, M., Hevor, T., and Cloix, J. F. (2000). Correlation between brain glycogen and convulsive state in mice subjected to methionine sulfoximine. Life Sci. 67, 1773–1781.

Berdardinielli, Y., Magistretti, P. J., and Chatton, J. Y. (2004). Astrocytes generate Na+-mediated metabolic waves. Proc. Natl. Acad. Sci. U.S.A. 101, 14937–14942.

Bettler, B., Kaufmann, K., Mosbacher, J., and Gassmann, M. (2004). Monocarboxylate transporter 4 (MCT4) in glioma cells and in cultured astrocytes. J. Neurochem. 95, 209–219.

Bouzier-Sore, A. K., Merle, M., Magistretti, P. J., and Pellerin, L. (2002). Feeding active neurons: (re)emergence of a nursing role for astrocytes. J. Physiol. Paris 96, 273–282.

Braak, H., and Braak, E. (1988). Neuritophils threads occur in dendrites of tangle-bearing nerve cells. Neurosci. Lett. 85, 39–44.

Bradley, K. K., Jaggar, J. H., Bonev, A. D., Hepper, T. J., Flynn, E. R., Nelson, M. T., et al. (1999). Kir2.1 encodes the inward rectifier potassium channel in rat arterial smooth muscle cells. J. Physiol. 515(Pt 3), 639–651.

Brain, E. F., Jr., Heistad, D. D., and Faraci, F. M. (1994). Effect of carbon monoxide on rabbit cerebral arteries. Stroke 25, 639–643: discussion 643–634.

Brown, A. M., Sickmann, H. M., Fosgerau, K., Lund, T. M., Schousboe, A., Waagepetersen, H. S., et al. (2005). Astrocyte glycogen metabolism is required for neural activity during aglycemia or intense stimulation in mouse white matter. J. Neurosci. Res. 79, 74–80.

Brown, A. M., Tsekko, S. B., and Ransom, B. R. (2003). Glycogen regulation and functional role in mouse white matter. J. Physiol. 549, 501–512.

Bushong, E. A., Martone, M. E., Jones, Y. Z., and Ellisman, M. H. (2002). Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J. Neurosci. 22, 183–192.

Cao, X. H., Hashemi, P., Douhou, A., Bonvanto, G., Bouteille, M. G., Walls, A. B., et al. (2008). Glutamate receptor-dependent increments in lactate, glucose and oxygen metabolism evoked in rat cerebellum in vivo. J. Physiol. 586, 1337–1349.

Chan, H. S., et al. (2005). Astrocyte glycogen metabolism is required for intense stimulation in mouse white matter. J. Neurosci. Res. 79, 74–80.

Choi, J. F., and Hevor, T. (2009). Epilepsy, regulation of brain energy metabolism and neurotransmission. Curr. Med. Chem. 16, 841–853.

Cloutier, M., Bolger, F. B., Lowry, J. P., and Wellstead, P. (2009). An integrative dynamic model of brain energy metabolism using in vivo biochemical measurements. J. Comput. Neurosci. 27, 391–414.

Contreras, J. E., Sanchez, H. A., Eugenin, E. A., Speidel, D., Theis, M., Willecke, K., et al. (2002). Metabolic inhibition induces opening of unopposed connexin 43 gap junction hemichannels and reduces gap junctional communication in cortical astrocytes in culture. Proc. Natl. Acad. Sci. U.S.A. 99, 495–500.

Coimbra, M. L., Kang, J., Lin, J. H., Bueno, E., Hansen, T. W., He, L., et al. (1998). Astrocytic gap junctions remain open during ischemic conditions. J. Neurosci. 18, 2520–2537.

Csernansky, J. G., Bardgett, M. E., Sheline, Y. I., Morris, J. C., and Olney, J. W. (1996). CSF excitatory implications for cellular bioenergetics. Eur. J. Neurosci. 12, 3843–3853.

Chaudhry, E. A., Schmitz, D., Reimer, R. J., Larsson, P., Gray, A. T., Nicoll, R., et al. (2002). Glutamine uptake by neurons: interaction of protons with system a transporters. J. Neurosci. 22, 62–72.

Chen, Y., and Swanson, R. A. (2003). The glutamate transporters EAAT2 and EAAT3 mediate cysteine uptake in cortical neuron cultures. J. Neurochem. 84, 1332–1339.

Chih, C. P., and Roberts, E. L. Jr. (2003). Energy substrates for neurons during neural activity: a critical review of the astrocyte-neuron lactate shuttle hypothesis. J. Cereb. Blood Flow Metab. 23, 1263–1281.

Cho, Y., and Bannai, S. (1990). Uptake of glutamate and cysteine in C-6 glioma cells and in cultured astrocytes. J. Neurochem. 55, 2091–2097.

Chodet, N., Pellerin, L., Welker, E., Lacombe, P., Seylaz, J., Magistretti, P., et al. (2001). Local injection of antisense oligonucleotides targeted to the glial glutamate transporter GLAST decreases the metabolic response to somatosensory activation. J. Cereb. Blood Flow Metab. 21, 404–412.

Chow, S. K., Yu, D., Macdonald, C. L., Buibas, M., and Silva, G. A. (2010). Amyloid-beta-peptide directly induces spontaneous calcium transients, delayed intercellular calcium waves and gliosis in rat cortical astrocytes. ASN Neuro 2:e00026. doi: 10.1042/AN20090035.

Cloix, J. F., and Hevor, T. (2009). Mitochondrial metabolism and neurotransmission. Curr. Med. Chem. 16, 841–853.

Cloutier, M., Bolger, F. B., Lowry, J. P., and Wellstead, P. (2009). An integrative dynamic model of brain energy metabolism using in vivo biochemical measurements. J. Comput. Neurosci. 27, 391–414.

Cotrina, M. L., Kang, J., Lin, J. H., Bueno, E., Hansen, T. W., He, L., et al. (1998). Astrocytic gap junctions remain open during ischemic conditions. J. Neurosci. 18, 2520–2537.

Csernansky, J. G., Bardgett, M. E., Sheline, Y. I., Morris, J. C., and Olney, J. W. (1996). CSF excitatory implications for cellular bioenergetics. Eur. J. Neurosci. 12, 3843–3853.
Dorrance, A. M., Rupp, N., Dong, X. X., Wang, Y., and Qin, Z. (2004). The role of glial membrane ion channels in seizures and epileptogenesis. Pharmacol. Ther. 103, 95–108.

Danbolt, N. C. (2001). Glutamate uptake. Prog. Neurobiol. 65, 1–105.

Del Zoppo, G. J. (2010). The neurovascular unit in the setting of stroke. J. Intern. Med. 267, 156–171.

Del Zoppo, G. J., and Mabuchi, T. (2003). Cerebral microvascular responses to focal ischemia. J. Cereb. Blood Flow Metab. 23, 879–894.

Devor, A., Tian, P., Nishimura, N., Teng, I. C., Hillman, E. M., Narayanan, S. N., et al. (2007). Suppressed neuronal activity and concurrent arteriolar vasoconstriction may explain negative blood oxygen level-dependent signal. J. Neurosci. 27, 4452–4459.

D’Ambrosio, R. (2004). The role of glial acid (AUDA), reduces ischemic lactate supply for neighboring cells. Acta Pharmacol. Sin. 25, 379–387.

D. M., Newman, J. W., Hammock, B. D., and Heiss, J. D., et al. (2007). 2-Hydroxy-6B with mesial temporal lobe hypometabolism in temporal lobe epilepsy. J. Neurochem. 59, 606–610.

Dong, X. X., Wang, Y., and Qin, Z. H. (2009). Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30, 379–387.

Dorrance, A., Rupp, N., Pollock, D. M., Newman, J. W., Hammock, B. D., and Imig, J. D. (2005). An epoxy hydroxylase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmac. 46, 842–848.

Dringe, R., Gebhardt, R., and Hamprecht, B. (1993). Glycogen in astrocytes: possible function as lactate supply for neighboring cells. Brain Res. 623, 208–214.

Dringe, R., and Hamprecht, B. (1993). Differences in glycogen metabolism in astroglia-rich primary cultures and sorbitol-selected astroglial cultures derived from mouse brain. Glia 8, 143–149.

Dudek, F. E., Patrylo, P. R., and Wuarin, J. P. (1999). Mechanisms of neuronal synchronization during epileptiform activity. Adv. Neurol. 79, 699–708.

Duffy, S., and Mavricar, B. A. (1995). Adrenergic calcium signaling in astrocyte networks within the hippocampal slice. J. Neurosci. 15, 5535–5550.

Dunn, K. M., and Nelson, M. T. (2010). Potassium channels and neurovascular coupling. Circ. J. 74, 608–616.

Dunn, K. M., Renic, M., Flach, A. K., Harder, D. R., Falck, J., and Roman, R. J. (2008). Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 295, H2455–H2465.

Earley, S., Heppner, T. J., Nelson, M. T., and Brayden, J. E. (2005). TRPV4 forms a novel Ca2+-signaling complex with ryanodine receptors and BKCa channels. Circ. Res. 97, 1270–1279.

Edmond, J., Robbins, R. A., Bergstrom, J. D., Cole, R. A., and De Vellis, J. (1987). Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. J. Neurosci. Res. 18, 551–561.

Ed, T., Lee, T. S., Thomas, M. J., Amiry-Moghaddam, M., Bjorsem, L. P., Spencer, D. D., et al. (2005). Loss of perivascular aquaporin 4 may underlie deficient water and K+ homeostasis in the human epileptogenic hippocampus. Proc. Natl. Acad. Sci. U.S.A. 102, 1193–1198.

Ed, T., Thomas, M. J., Spencer, D. D., Runden-Pran, E., Lai, J. C., Malthankar, G. V., et al. (2004). Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet 363, 28–37.

Engel, J. Jr., Brown, W. J., Kuhl, D. E., Phelps, M. E., Mazziotta, J. C., and Crandall, P. H. (1982). Pathological findings underlying focal temporal lobe hypometabolism in partial epilepsy. Ann. Neurol. 12, 518–528.

Engel, J. Jr., Kuhl, D. E., Phelps, M. E., Rausch, R., and Nuwer, M. (1985). Local cerebral metabolism during partial seizures. Neurology 33, 400–413.

Effer, M.-I., L., and Albrecht, J. (1993). Hyperammonemia and hepatic encephalopathy stimulate rat cerebral synaptic mitochondrial glutamate dehydrogenase activity specifically in the direction of glutamate oxidation. Brain Res. 618, 299–302.

Farkas, E., and Luiten, P. G. (2001). Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog. Neurobiol. 64, 575–611.

Filosa, J. A., Bonev, A. D., and Nelson, M. T. (2004). Calcium dynamics in cortical astrocytes and arterioles during neurovascular coupling. Circ. Res. 95, e73–e81.

Filosa, J. A., Bonev, A. D., Straub, S. V., Meredith, A. L., Willerson, M. K., Aldrich, R. W., et al. (2006). Local potassium signaling couples neuronal activity to vasodilation in the brain. Nat. Neurosci. 9, 1397–1403.

Fiumana, E., Parfenova, H., Jaggar, J. H., and Leffler, C. W. (2003). Carbon monoxide mediates vasodilator effects of glutamate in isolated pressurized cerebral arteries of newborn pigs. Am. J. Physiol. Heart Circ. Physiol. 284, H1073–H1079.

Fleming, I. (2004). Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol. Res. 49, 525–533.

Fonnum, F. (1984). Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42, 1–11.

Fossati, P., Turpin, F. R., Sacchi, S., Dulong, J. Shi, T., Rivet, J. M., et al. (2012). Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex. Cereb. Cortex 22, 595–606.

Fotheringham, I., Donati, D., Akhyani, N., Fogdell-Hahn, A., Vortmeyer, A., Heiss, J. D., et al. (2007). Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med. 4:e180. doi: 10.1371/journal.pmed.0040180

Fowler, J. C. (1993). Glucose deprivation results in a lactate preventable increase in adenosine and depression of synaptic transmission in rat hippocampal slices. J. Neurochem. 60, 572–576.

Fremeau, R. T. Jr., Kam, K., Qureshi, T., Johnson, I., Copenhagen, D. R., Storm-Mathisen, J., et al. (2004). Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 304, 1813–1819.

Fujimoto, Y., Uno, E., and Sakuma, S. (2004). Effects of reactive oxygen and nitrogen species on synaptic plasticity during learning in 1-day-old chick by facilitation of astrocytic oxidative metabolism: implications for Alzheimer’s disease. J. Neurochem. 109(Suppl. 1), 230–236.

Gibbs, M. E., Anderson, D. G., and Hertz, L. (2006). Inhibition of glycogenolysis in astrocytes interrupts memory consolidation in young chickens. Glia 54, 214–222.

Gibbs, M. E., Gibbs, Z., and Hertz, L. (2009). Rescue of Abeta(1-42)-induced memory impairment in day-old chick by facilitation of astrocytic oxidative metabolism: implications for Alzheimer’s disease. J. Neurochem. 109(Suppl. 1), 230–236.

Gibbs, M. E., and Hertz, L. (2008). Inhibition of astrocytic energy metabolism by D-lactate exposure impairs memory. Neurochem. Int. 52, 1012–1018.

Gibbs, M. E., Lloyd, H. G., Santa, T., and Hertz, L. (2007). Glycogen is a preferred glutamate precursor during learning in 1-day-old chick: biochemical and behavioral evidence. J. Neurosci. Res. 85, 3326–3333.

Giroud, H., Bonev, A. D., Hannah, R. M., Meredith, A., Aldrich, R. W., and Nelson, M. T. (2010). Astrocytic endfoot Ca2+ and BK channels determine both arteriolar dilation
Stobart and Anderson

Astrocytes as gatekeepers of neuronal energy supply

Haberg, A., Qu, H., Saether, O., Uansgard, G., Haraldseth, O., and Sonnewald, U. (2001). Differences in neurotransmitter synthesis and intermediary metabolism between glutamatergic and GABAergic neurons during 4 hours of middle cerebral artery occlusion in the rat: the role of astrocytes in neuronal survival. J. Cereb. Blood Flow Metab. 21, 1451–1463.

Haller, M. A., Fallin, T., Takano, H., Dong, J. H., and Haydon, P. G. (2007). Synaptic islands defined by the territory of a single astrocyte. J. Neurosci. 27, 6473–6477.

Harder, D. R., Narayanan, J., Birks, E. K., Liard, J. F., Imig, J. D., Lombard, J. H., et al. (1996). Identification of a putative microvascular oxygen sensor. Circ. Res. 79, 54–61.

Harssinger, T., Guthrie, P. B., Atkinson, P. B., Bennett, M. V., and Kater, S. B. (1996). An extracellular signaling component in propagation of astrocytic calcium waves. Proc. Natl. Acad. Sci. U.S.A. 93, 13268–13273.

Haughery, N. J., and Mattson, M. P. (2003). Alzheimer’s amyloid beta-peptide enhances ATP/gap junction-mediated calcium wave propagation in astrocytes. Neuronol. Med. 3, 173–180.

He, V., Janssen, W. G., Rothstein, J. D., and Morrison, J. H. (2000). Differential synaptic localization of the glutamate transporters EAAC1 and glutamate receptor subunit GluR2 in the rat hippocampus. J. Comp. Neurol. 418, 255–269.

Henneberger, C., Papoupin, T., Oliet, S. H., and Rusakov, D. A. (2010). Long-term potentiation depends on release of D-serine from astrocytes. Nature 463, 232–236.

Henneberger, C., and Rusakov, D. A. (2010). Synaptic plasticity and Ca2+ signalling in astrocytes. Neuron Glia Biol. 6, 141–146.

Herrande-Mendez, A., Almeida, A., Fernandes, E., Maestre, C., Moncada, S., and Bolanos, J. P. (2009). The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell. Biol. 11, 747–757.

Hertz, L., and Ebert, H. R. (2004). Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci. 27, 733–743.

Higashimori, H., Blanco, V. M., Tuniki, V. R., Falck, J. R., and Filosa, J. A. (2010). Role of eicosyseicosatrienic acids as autocrine metabolites in glutamate-mediated K+ signaling in perivascular astrocytes. Am. J. Physiol. Cell Physiol. 299, C1068–C1078.

Hillered, L., Hallström, A., Segersvard, S., Persson, L., and Ungerstedt, U. (1989). Dynamics of extracellular metabolites in the striatum after middle cerebral artery occlusion in the rat monitored by intracerebral microdialysis. J. Cereb. Blood Flow Metab. 9, 607–616.

Hirrlinger, J., and Dringen, R. (2010). The cystolic redox state of astrocytes: maintenance, regulation and functional implications for metabotlite trafficking. Brain Res. Rev. 63, 177–188.

Hiyama, T. Y., Watanabe, E., Kondo, H., and Noda, M. (2004). The subfornical organ is the primary locus of sodium–level sensing by Na(x) channels for the control of salt-intake behavior. J. Neurosci. 24, 9276–9281.

Hiyama, T. Y., Watanabe, E., Ono, K., Inenaga, K., Tamkun, M. M., Yoshida, S., et al. (2002). Na(+) channel involved in CNS sodium-level sensing. Nat. Neurosci. 5, 511–512.

Holt, D. C., Fedinec, A. L., Vaughn, A. N., and Ebert, H. R. (2007). Age and species dependence of pial arteriolar responses to topical carbon monoxide in vivo. Exp. Biol. Med. (Maywood) 223, 1465–1469.

Hu, Y., and Wilson, G. S. (1997). A temporay local energy pool coupled to neuronal activity: fluctuations of extracellular lactate levels in rat brain monitored with rapid-response enzyme-based sensor. J. Neurochem. 69, 1484–1490.

Iadecola, C. (2004). Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat. Rev. Neurosci. 5, 347–360.

Idestrup, C. P., and Salter, M. W. (1998). P2Y and P2U receptors differentially release intracellular Ca2+ via the phospholipase c/inositol 1, 4, 5-trisphosphate pathway in astrocytes from the dorsal spinal cord. Neuroscience 86, 913–923.

Ignarro, J. L., Cirino, G., Casini, A., and Napoli, C. (1999). Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 34, 879–886.

Imig, J. D., and Hammock, B. D. (2009). Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8, 794–805.

Ishikawa, M., Kajimura, M., Adachi, T., Maruyama, K., Makino, N., Goda, N., et al. (2005). Carbon monoxide from hemoglobinase-2 Is a tonic regulator against NO-dependent vasodilatation in the adult rat cerebral microcirculation. Circ. Res. 97, e104–e114.

Izumi, Y., Katsuki, H., and Zorumski, C. F. (1997). Monocarboxylates (pyruvate and lactate) as alternative energy substrates for the induction of long-term potentiation in rat hippocampal slices. Neurosci. Lett. 232, 17–20.

Jackson, M., Song, W., Liu, M. Y., Jin, L., Dykes-Hoberg, M., Lin, C. I., et al. (2001). Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature 410, 89–93.

Jaggar, J. H., Leffler, C. W., Cheranov, S. Y., Tcheranova, D. E., S., and Cheng, X. (2002). Carbon monoxide dilates cerebral arteries by enhancing the coupling of Ca2+ sparks to Ca2+-activated K+ channels. Circ. Res. 91, 610–617.

Jamiesson, D., and Vandenbreek, H. A. (1963). Measurement of oxygen tensions in cerebral tissues of rats exposed to high pressures of oxygen. J. Appl. Physiol. 18, 869–876.

Jimenez-Jimeenez, F. I., Molina, J. A., Gomez, P., Vargas, C., De Bustos, F., Benito-Leon, J., et al. (1998). Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer’s disease. J. Neural Transm. 105, 269–277.

Jourdain, P., Bergersen, L. H., Bhaakaurally, K., Bezzi, P., Santello, M., Domercq, M., et al. (2007).
Glutamate exocytosis from astrocytes controls synaptic strength. *Nat. Neurosci.* 10, 331–339.

Juranka, I., Suzuki, H., and Yamamoto, S. (1999). Affinities of various mammalian arachidonate lipoxigenases and cyclooxygenases for molecular oxygen as substrate. *Biochim. Biophys. Acta* 1436, 509–518.

Juurlink, B. H. (1997). Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. *Neurosci. Biobehav. Rev.* 21, 151–166.

Kacem, K., Lacombe, P., Seylaz, J., and Bonvento, G. (1998). Structural organization of the perivascular astrocyte endfoot and their relationship with the endothelial glucose transporter: a confocal microscopy study. *Glia* 23, 1–10.

Kang, J., Jiang, L., Goldman, S. A., and Nedergaard, M. (1998). Astrocyte-mediated potentiation of inhibitory synaptic transmission. *Nat. Neurosci.* 1, 683–692.

Kanu, A., Gilpin, D., Fedinec, A. L., and Leffler, C. W. (2006). Cyclooxygenase products stimulate carbon monoxide production by piglet cerebral microvessels. *Exp. Biol. Med. (Maywood)* 231, 181–185.

Kanu, A., and Leffler, C. W. (2009). Roles of glia liminants astrocyte and carbon monoxide in adenosine diphosphate-induced pial arteriolar dilation in newborn pigs. *Stroke* 40, 930–935.

Kanu, A., and Leffler, C. W. (2011). Arachidonic acid- and prostaglandin E2-induced cerebral vasodilation is mediated by carbon monoxide, independent of reactive oxygen species in piglets. *Am. J. Physiol. Heart Circ. Physiol.* 301, H2482–H2487.

Kasischke, K. A. (2008). A new pathway for lactate production in the CNS. *J. Physiol.* 586, 1207–1208.

Kasischke, K. A., Vishwasrao, H. D., Fisher, P. J., Zipfel, W. R., and Webb, W. W. (2004). Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. *Science* 305, 99–103.

Kimmelberg, H. K., Goderie, S. K., Higman, S., Pang, S., and Wannemius, R. A. (1999). Swelling-induced release of glutamate, aspartate, and taurine from astrocyte cultures. *J. Neurosci.* 19, 1595–1603.

Kishore, P., Boucau, L., Zhang, K., Li, W., Koppaka, S., Kehlenbrink, S., et al. (2011). Activation of K(ATP) channels suppresses glucose production in humans. *J. Clin. Invest.* 121, 4916–4920.

Knecht, K. R., Milam, S., Wilkinson, D. A., Fedinec, A. L., and Leffler, C. W. (2010). Time-dependent action of carbon monoxide on the newborn cerebrovascular circulation. *Am. J. Physiol. Heart Circ. Physiol.* 299, H70–H75.

Knot, H. J., and Nelson, M. T. (1998). Regulation of arterial diameter and wall (Ca2+)- in cerebral arteries of rat by membrane potential and intravascular pressure. *J. Physiol.* 508(Pt 1), 199–209.

Knot, H. J., Zimmermann, P. A., and Nelson, M. T. (1996). Extracellular K(+) induced hyperpolarizations and dilatations of rat coronary and cerebral arteries involve inward rectifier K(+) channels. *J. Physiol.* 492(Pt 2), 419–430.

Kofuji, P., and Newman, E. A. (2004). Potassium buffering in the central nervous system. *Neuroscience* 129, 1045–1056.

Koizumi, J. (1974). Glycogen in the hippocampal region of the rat. *J. Physiol.* 231, 1–37.

Kovacs, R., Heinemann, U., and Steinhauser, C. (2012). Mechanisms underlying blood-brain barrier dysfunction in brain pathology and epileptogenesis: role of astroglia. *Epilepsia* 53(Suppl. 6), 53–59.

Kuchibhotla, K. V., Lattarulo, C. R., Hyman, B. T., and Bacsai, B. J. (2009). Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. *Science* 323, 1211–1215.

Kuhl, D. E., Engel, J. Jr., Phelps, M. E., and Selin, C. (1980). Epileptic patients with temporal lobe epilepsy: a clinical, radiological and EEG study. *J. Neurosci.* 32, 930–935.

Li, A., Xi, Q., Umstot, E. S., Bellner, J., Harder, D. R., and Koehler, R. C. (2008). Interaction of nitric oxide, 20-HETE, and EETs during functional hyperemia in whisker barrel cortex. *Am. J. Physiol. Heart Circ. Physiol.* 295, H619–H631.

Liu, X., Li, C., Gebremedhin, D., Hwang, S. H., Hammock, B. D., Falck, J. R., et al. (2011). Epoxycycloartenol acid-dependent cerebral vasodilation evoked by metabotrophic glutamate receptor activation in vivo. *Am. J. Physiol. Heart Circ. Physiol.* 301, H373–H381.

Lorente-Folch, I., Sahun, I., Contreras, L., Casarejos, M. J., Grau, J. M., Saheki, T., et al. (2013). AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. *J. Neurochem.* 124, 347–362.

Loaiza, A., Porras, O. H., and Barros, L. F. (2003). Glutamate triggers rapid glucose transport stimulation in astrocytes as evidenced by real-time confocal microscopy. *J. Neurosci.* 23, 7337–7342.

Magistretti, P. J. (2006). Neuron-glial metabolic coupling and plasticity. *J. Exp. Biol.* 209, 2304–2311.

Magistretti, P. J., and Pellerin, L. (1999). Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 354, 1155–1163.

Magistretti, P. J., Pellerin, L., Rothman, D. L., and Shulman, R. G. (1999).
Energy on demand. Science 283, 496–497.

Mangia, S., Garreffa, G., Bianciardi, M., Gove, F., Di Salle, F., and Maraviglia, B. (2003). The aerobic brain: lactate decrease at the onset of neural activity. *Neuroscience* 118, 7–10.

Mangia, S., Simpson, I. A., Vannucci, S. J., and Carruthers, A. (2009). The in vivo neuron-to-astrocyte lactate shuttle in human brain: evidence from modeling of measured lactate levels during visual stimulation. *J. Neurochem.* 109(Suppl. 1), 55–62.

Mangia, S., Tkac, I., Gruetter, R., Van De Moortele, P. F., Maraviglia, B., and Ugurbil, K. (2007). Sustained neuronal activation raises oxidative metabolism to a new steady-state level: evidence from 1H NMR spectroscopy in the human visual cortex. *J. Cereb. Blood Flow Metab.* 27, 1038–1047.

Martínez-Hernandez, A., Bell, K. P., and Norenberg, M. D. (1977). Glutamine synthetase: glial localization in brain. Science 195, 1356–1358.

Maslia, E., Alford, M., Mallory, M., Rockenstein, E., Moehrs, D., and Van Leuven, F. (2000). Abnormal glutamate transport function in mutant amyloid precursor protein transgenic mice. *Exp. Neurol.* 163, 381–387.

Maus, M., Marin, P., Israel, M., Głowinski, J., and Premont, J. (1999). Pyruvate and lactate protect striatal neurons against N-methyl-D-aspartate-induced neurotoxicity. *Eur. J. Neurosci.* 11, 3213–3224.

McCaulin, A. E., Chen, B. R., Radosевич, A. J., Cauli, B., and Hillman, E. M. (2011). In vivo 3D morphology of astrocyte-vascularule interactions in the somatosensory cortex: implications for neurovascular coupling. *J. Cereb. Blood Flow Metab.* 31, 795–806.

McCormick, D. A., and Conteras, D. (2001). On the cellular and network bases of epileptic seizures. *Annu. Rev. Physiol.* 63, 815–846.

McKenna, M. C. (2007). The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. *J. Neurosci.* 35, 3347–3358.

McKenna, M. C., Hopkins, I. B., Lindauer, S. L., and Bamford, P. (2006a). Aspartate aminotransferase in synaptic and nonsynaptic mitochondria: differential effect of compounds that influence transient hetero-enzyme complex (metabolon) formation. *Neurochem. Int.* 48, 629–636.

McKenna, M. C., Waagepetersen, H. S., Schousboe, A., and Sonnewald, U. (2006b). Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. *Biochem. Pharmacol.* 71, 399–407.

McKenna, M. C., Tildon, J. T., Stevenson, J. H., Boatrigh, R., and Huang, S. (1993). Regulation of energy metabolism in synaptic terminals and cultured rat brain astrocytes: differences revealed using aminooxyacetate. *Dev. Neurosci.* 15, 320–329.

McKinnon, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. *Neurology* 34, 939–944.

Meier, S. D., Kafitz, K. W., and Rose, C. R. (2008). Developmental profile and mechanisms of GABA-induced calcium signaling in hippocampal astrocytes. *Glia* 56, 1127–1137.

Mentsis, M. J., Horwitz, B., Grady, F. L., Alexander, G. E., Vannemeter, J. M., and Maag, J. M., et al. (1996). Visual cortical dysfunction in Alzheimer’s disease evaluated with a temporally graded “stress test” during PET. *Am. J. Psychiatry* 153, 32–40.

Merlini, M., Meyer, E. P., Ulmann-Schuler, A., and Nitsch, R. M. (2011). Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic a beta mouse. *Acta Neuropathol.* 122, 293–311.

Merz, P. A., Wisniewski, H. M., Somerville, R. A., Bobin, S. A., Masters, C. L., and Iqbal, K. (1983). Ultrastructural morphology of amyloid fibrils from neuritic and cerebral amyloid plaques. *J. Ultrastruct. Mol. Struct. Res.* 82, 5606–5611.

Moffett, D. E., L. T., and Hillman, E. M. (2011). Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. *Ann. N.Y. Acad. Sci.* 1147, 180–195.

Mothet, J. P., Pollegioni, L., Morikawa, T., Kajimura, M., and Ugurbil, K. (2007). Glial cells dilate and constrict blood vessels: a mechanism of strict blood vessels: a mechanism of glycolytic-induced neuronal expression of mitochondrial glyceraldehyde-3-phosphate dehydrogenase. *J. Neurochem.* 85, 831–842.

Nicholls, D. G. (2004). Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. *Curr. Mol. Med.* 4, 149–177.

Nicholls, D. G., Johnson-Cadwell, L., Vesce, S., Jakabsons, M., and Yadava, N. (2007). Bioenergetics of mitochondria in cultured neurons and their role in glutamate excitotoxicity. *J. Neurosci.* 35, 3206–3212.

Niwa, K., Porter, V. A., Kazama, K., Cornfeld, D., Carlson, G. A., and Iadecola, C. (2001). A beta-peptide enhances vasoconstriction in cerebral circulation. *Am. J. Physiol. Heart Circ. Physiol.* 281, H2417–H2424.

Niwa, K., Younikin, L., Ebeling, C., Turner, S. K., Westaway, D., Younikin, S., et al. (2000). Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. *Proc. Natl. Acad. Sci. U.S.A.* 97, 9735–9740.

O’Hara, J. A., Hou, H., Demidenko, E., Springett, R. J., Khan, N., and Swartz, H. M. (2005). Simultaneous measurement of rat brain cortex P-oxygen using EPR oximetry and a fluorescence fiber-optic sensor during normoxia and hyperoxia. *Physiol. Meas.* 26, 203–213.

Oberein, N. A., Wang, X., Goldman, S., and Nedergaard, M. (2006). Astrocytic complexity distinguishes the human brain. *Trends Neurosci.* 29, 547–553.
Pascual, J. M., Carceller, F., Roda, J. M., Parpura, V., Basarsky, T. A., Liu, Park, L., Anrather, J., Forster, C., Pannasch, U., Vargova, L., Reingruber, J., Ezan, P., Holcman, D., Gaume, C., et al. (2011). Astroglial networks scale synaptic activity and plasticity. Proc. Natl. Acad. Sci. U.S.A. 108, 8467–8472.

Pardo, B., Rodrigues, T. B., Contreras, L., Garzon, M., Llorente-Folch, L., Kobayashi, K., et al. (2011). Brain glutamine synthesis requires neuronal-born aspartate as amino donor for glial glutamate formation. J. Cereb. Blood Flow Metab. 31, 90–101.

Parfenova, H., Tcheranova, D., Basuroy, S., Fedinec, A. L., Liu, J., and Leffler, C. W. (2012). Functional role of astrocyte glutamate receptors and carbon monoxide in mouse vasodilation response to glutamate. Am. J. Physiol. Heart Circ. Physiol. 302, H2257–H2266.

Park, L., Anrather, J., Forster, C., Kazama, K., Carlson, G. A., and Iadecola, C. (2004). Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J. Cereb. Blood Flow Metab. 24, 334–342.

Parpura, V., Basarsky, T. A., Liu, F., Jefinjina, K., Jefinjina, S., and Haydon, P. G. (1994). Glutamate-mediated astrocyte-neuron signalling. Nature 369, 744–747.

Pascual, J. M., Carceller, F., Roda, J. M., and Gerdan, S. (1998). Glutamate, glutamine, and GABA as substrates for the neuronal and glial compartments after focal cerebral ischemia in rats. Stroke 29, 1048–1056. Discussion: 1056–1047.

Paulson, O. B., and Newman, E. A. (1987). Does the release of potassium from astrocyte endfeet regulate cerebral blood flow? Science 237, 890–892.

Pellegrini, G., Rossier, C., Magistretti, P. J., and Martin, J. L. (1996). Cloning, localization and induction of mouse brain glycogen synthase. Brain Res. Mol. Brain Res. 38, 191–199.

Pellerin, L., and Magistretti, P. J. (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. U.S.A. 91, 10625–10629.

Pellerin, L., Pellegrini, G., Bittar, P. G., Charnay, Y., Bouras, C., Martin, J. L., et al. (1998a). Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev. Neurosci. 20, 291–299.

Pellerin, L., Pellegrini, G., Martin, J. L. and Magistretti, P. J. (1998b). Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc. Natl. Acad. Sci. U.S.A. 95, 3990–3995.

Peng, L., Gu, L., Zhang, H., Huang, X., Hertz, E., and Hertz, I. (2007). Glutamate as an energy substrate in cultured neurons during glucose deprivation. J. Neurosci. Res. 85, 3480–3486.

Peng, L., Zhang, X., and Hertz, L. (1994). High extracellular potassium concentrations stimulate oxidative metabolism in a gluta- matergic neuronal culture and glycolysis in cultured astrocytes but have no stimulatory effect in a GABAergic neuronal culture. Brain Res. 663, 168–172.

Peng, X., Carhuapoma, J. R., Bhardwaj, A., Alkayed, N. J., Falck, J. R., Harder, D. R., et al. (2002). Suppression of cortical functional hyperemia to vibrissal stimulation in the rat by ephoxeigenase inhibitors. Am. J. Physiol. Heart Circ. Physiol. 283, H2029–H2037.

Perea, G., and Araque, A. (2007). Astrocytes potentiate transmitter release at single hippocampal synapses. Science 317, 1083–1086.

Petravick, J., Fiacco, T. A., and McCarthy, K. D. (2008). Loss of IP3 receptor-dependent Ca2+ increases in hippocampal astrocytes does not affect baseline Ca1 pyramidal neu- ronal synaptic activity. J. Neurosci. 28, 4967–4973.

Phelps, C. H. (1972). Barbiturate-induced glycogen accumulation in brain. An electron microscopic study. Brain Res. 39, 225–234.

Phillis, J. W., Ren, J., and O’Regan, M. H. (2000). Transporter reversal as a mechanism of hepatic release from the ischemic rat cerebral cortex: studies with DL-threo- beta-benzylxoyaspartate. Brain Res. 868, 105–112.

Pierre, K., Magistretti, P. J., and Pellerin, L. (2002). MCT2 is a major neuronal monocarboxylate transporter in the adult mouse brain. J. Cereb. Blood Flow Metab. 22, 586–585.

Pines, G., Danbolt, N. C., Bjoras, M., Zhang, Y., Bendahan, A., Eide, L., et al. (1992). Cloning and expression of a rat brain L-glutamate transporter. Nature 360, 460–467.

Pocai, A., Lam, T. K., Gutierrez-Juarez, R., Obici, S., Schwartz, G. J., Bryan, J., et al. (2005). Hypothalamic KAT1 channels control hepatic glucose production. Nature 434, 1026–1031.

Poloyac, S. M., Zhang, Y., Bies, R. R., Kochanek, P. M., and Graham, S. H. (2006). Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J. Cereb. Blood Flow Metab. 26, 1551–1561.

Porras, O. H., Loaiza, A., and Barros, L. F. (2004). Glutamate mediates acute glucose transport inhibition in hip- pocampal neurons. J. Neurosci. 24, 9669–9673.

Porras, O. H., Ruminot, I., Loaiza, A., and Barros, L. F. (2008). Na+/K(+)–Ca(2+) co-signaling in the stimulation of the glucose transporter GLUT1 in cultured gliia. Glia 56, 59–68.

Porter, J. T., and McCarthy, K. D. (1996). Hippocampal astrocytes in situ respond to glutamate released from synaptic terminals. J. Neurosci. 16, 5073–5081.

Price, D. L., Ludwig, J. W., Mi, H., Schwarz, T. L., and Ellisman, M. H. (2002). Distribution of rFluoCA2+- activated K+ channels in rat astrocyte perivascular endfeet. Brain Res. 956, 183–193.

Prichard, J., Rothman, D., Novotny, E., Petroff, O., Kuwabara, T., and Alzheimer’s disease. Cell Death Differ. 16, 378–385.

Rosi, D. J., Brady, J. D., and Mohr, K. (2007). Astrocyte metabolism and signaling during brain ischemia. Nat. Neurosci. 10, 1377–1386.

Rothstein, J. D., Martin, L., Levey, A. I., Dykes-Hoberg, M., Jän, L., Wt, D., et al. (1994). Localization of neuronal and glial gluta- mate transporters. Neuron 13, 713–725.

Rouach, N., Avignone, E., Merne, W., Koulakoff, A., Venance, L., Blomstrand, F., et al. (2002). Gap junctions and connexin expression in the normal and pathological central nervous system. Biol. Cell 94, 457–475.
Rouach, N., Koulakoff, A., Abedara, V., Willecke, K., and Giaume, C. (2008). Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 322, 1551–1555.

Ruminot, L., Gutierrez, R., Pena, M., Agostino, C., Sotelo-Hitschfeld, T., Lerchundi, R., et al. (2011). NBCe1 mediates the acute stimulation of astrocytic glycolysis by extracellular K+-J. Neurosci. 31, 14264–14271.

Rutte, J., Reich, M., Wu, L. C., and McIntyre, S. L. (2001). Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293, 510–514.

Sagar, S. M., Sharp, F. R., and Swanson, R. A. (1987). The regional distribution of glycogen in rat brain fixed by microwave irradiation. Brain Res. 417, 172–174.

San Martin, A., Ceballo, S., Ruminot, I., Gutierrez, R., Pena, S., and Stobart and Anderson Astrocytes as gatekeepers of neuronal energy supply.

Schild, L., Huppelsberg, J., Kahlert, A. B., Bak, L. K., and Waagepetersen, R. A. (1987). The regional distribution of astrocytic lactate in rat spinal roots. Brain Res. 322, 25454–25460.

Schummers, J., Yu, H., and Sur, M. (2008). Tuned responses of astrocytes and their influence on hemodynamic signals in the visual cortex. Science 320, 1638–1643.

Schurr, A. (2006). Lactate: the ultimate cerebral oxidative energy substrate? J. Cereb. Blood Flow Metab. 26, 142–152.

Schurr, A., Miller, J. J., Payne, R. S., and Rigor, B. M. (1999). An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons. J. Neurosci. 19, 34–39.

Schurr, A., Payne, R. S., Miller, J. J., and Rigor, B. M. (1997). Brain lactate, not glucose, fuels the recovery of synaptic function from hypoxia upon reoxygenation: an in vitro study. Brain Res. 744, 105–111.

Schurr, A., West, C. A., and Rigor, B. M. (1988). Lactate-supported synaptic function in the rat hippocampal slice preparation. Science 240, 1326–1328.

Schwartz, M. W., Woods, S. C., Porte, Jr., J. C., Seeley, R. J., and Baskin, D. G. (2000). Central nervous system control of food intake. Nature 404, 661–671.

Scott, H. L., Pow, D. V., Tannenberg, A., and Porter, D. A., Dekosky, S. T., and Mufson, S. (2003). Lactate-supported synaptic transmission of the astrocytic glycogen-shunt. J. Neurosci. 23, 534–547.

Shashidharan, P., You, H., and Sur, H. S. (2005). Compartmentation of glutamate and glucose in cultured astrocytes: blockade by protein synthesis inhibition. J. Neurosci. 25, 1269–1281.

Shank, R. P., Bennett, G. S., Freytag, S. O., and Campbell, G. L. (1985). Pyruvate carboxylase: an astrocyte-specific enzyme implicated in the replenishment of amino acid neuromediator pools. Brain Res. 329, 364–377.

Shashidharan, P., Wittenberg, L., and Plaitakis, A. (1994). Molecular cloning of human brain glutamate/aspartate transporter II. Biochim. Biophys. Acta 1191, 393–396.

Shelton, M. K., and McCarthy, K. D. (2000). Hippocampal astrocytes exhibit Ca2+-elevating muscarinic cholinergic and histaminergic receptors in situ. J. Neurochem. 74, 553–563.

Sheppard, C. A., Simpson, P. B., Sharp, A. H., Nicofora, F. C., Ross, C. A., Lange, G. D., et al. (1997). Comparison of type 2 inositol 1,4,5-trisphosphate receptor distribution and subcellular Ca2+ release sites that support Ca2+-waves in cultured astrocytes. J. Neurochem. 68, 2317–2327.

Shigetomi, E., Krasun, S., Sofroniew, M. V., and Khakh, B. S. (2010). A genetically targeted optical sensor to monitor calcium signals in astrocyte processes. Nat. Neurosci. 13, 759–766.

Shigetomi, E., Tong, X., Kwan, K. Y., Corev, D. P., and Khakh, B. S. (2012). TRPA1 channels regulate astrocyte resting calcium and inhibitory synapse efficacy through GAT-3. Nat. Neurosci. 15, 70–80.

Shimizu, H., Watanabe, E., Hiyama, T. Y., Nakagura, A., Fujikawa, A., Okado, H., et al. (2007). Glial Nax channels control lactate signaling to neurons for brain [Na+] sensing. Nature 454, 59–72.

Shokati, T., Zwingmann, C., and Leibfritz, D. (2005). Contribution of extracellular glutamine as an anaplerotic substrate to neuronal metabolism: a re-evaluation by multinuclear NMR spectroscopy in primary cultured neurons. Neurochem. Res. 30, 1269–1281.

Shulman, R. G., Hyde, E., and Rothman, D. L. (2001). Cerebral energetics and the glycolgen shunt: neurochemical basis of functional imaging. Proc. Natl. Acad. Sci. U.S.A. 98, 6417–6422.

Sickmann, H. M., Schousboe, A., Fosgerau, K., and Waagepetersen, H. S. (2005). Compartmentation of lactate originating from glycolgen and glucose in cultured astrocytes. Neurochem. Res. 30, 1295–1304.

Sickmann, H. M., Walls, A. B., Schousboe, A., Bouman, S. D., and Waagepetersen, H. S. (2009). Functional significance of brain glycolgen in sustaining glutamate-glu neurotransmission. J. Neurochem. 109(Suppl. 1), 80–86.

Silver, I. A., Deas, J., and Erecinska, M. (1997). Ion homeostasis in brain cell: differences in intracellular ion responses to energy limitation between cultured neurons and glial cells. Neuroscience 78, 589–601.

Simard, M., Arcuino, G., Takano, T., Liu, Q. S., and Nederhaard, M. (2003). Signaling at the glial vascular interface. J. Neurosci. 23, 9254–9262.

Simpkins, A. N., Rudic, R. D., Schreihofer, D. A., Roy, S., Manhian, M., Tsai, H. J., et al. (2009). Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am. J. Pathol. 174, 2086–2095.

Simpson, I. A., Carruthers, A., and Vannucci, S. J. (2007). Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J. Cereb. Blood Flow Metab. 27, 1766–1791.

Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., et al. (2010). Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging 31, 578–590.

Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., Bookheimer, S. Y., et al. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 97, 6037–6042.

Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., et al. (1991). Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 88, 10540–10543.

Sontheimer, H. (1994). Voltage-dependent ion channels in glial cells. Glia 11, 156–172.

Sontheimer, H., and Waxman, S. G. (1993). Expression of voltage-activated ion channels by astrocytes and oligodendrocytes in the hippocampal slice. J. Neurophysiol. 70, 1863–1873.

Sorg, O., and Magistretti, P. J. (1992). Vasocative intestinal peptide and noradrenaline exert long-term control on glycerogen levels in astrocytes: blockade by protein synthesis inhibition. J. Neurosci. 12, 4923–4931.

Steele, M. L., and Robinson, S. R. (2012). Reactive astrocytes give neurons less support: implications for Alzheimer’s disease. Neurobiol. Aging 33, 423.e1–423.e13.
Sun, J., Druhan, L. J., and Zweier, J. L. (2008). Dose dependent effects of reactive oxygen and nitrogen species on the function of neuronal nitric oxide synthase. *Arch. Biochem. Biophys.* 471, 126–133.

Sun, W., McConnell, E., Pare, J. F., Xu, Q., Chen, M., Peng, W., et al. (2013). Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. *Science* 339, 197–200.

Suzuki, A., Stern, S. A., Bozdaglı, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., et al. (2011). Astrocyte-neuron lactate transport is required for long-term memory formation. *Cell* 144, 810–823.

Swanson, R. A., and Choi, D. W. (1993). Glial glycogen stores affect neuronal survival during glucose deprivation in *vitro*. *J. Cereb. Blood Flow Metab.* 13, 162–169.

Swanson, R. A., Sagar, S. M., and Sharp, F. R. (1989). Regional brain glycogen stores and metabolism during complete global ischemia. *Neuro. Res.* 11, 24–28.

Takano, T., Han, X., Deane, R., Zlokovic, B., and Nedergraad, M. (2007). Two-photon imaging of astrocytic Ca2+ signaling and the microvasculature in experimental mice models of Alzheimer’s disease. *Ann. N.Y. Acad. Sci.* 1097, 40–50.

Takano, T., Tian, G. F., Peng, W., Lou, N., Libionka, W., Han, X., et al. (2006). Astrocyte-mediated control of cerebral blood flow. *Nat. Neurosci.* 9, 260–267.

Takata, N., Mishima, T., Hisatsune, C., Nagai, T., Ebisu, E., Mikoshiba, K., et al. (2011). Astrocyte calcium signaling transfers cholinergic modulation to cortical plasticity in vivo. *J. Neurosci.* 31, 18155–18165.

Tanaka, K., Watanabe, M., Inoue, T., Yamaoka, Y., and Takahashi, K., et al. (1997). Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. *Science* 276, 1699–1702.

Tanaka, Y., Omura, T., Fukasawa, M., Horiuchi, N., Miyata, N., Minagawa, T., et al. (2007). Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats. *Neurosci. Res.* 59, 473–480.

Tekkot, S. B., Brown, A. M., Westenbroek, R., Pelierin, L., and Ransom, B. R. (2005). Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity. *J. Neurosci. Res.* 81, 644–652.

Thomas, T., Thomas, G., McLendon, C., Sutton, T., and Mullan, M. (1996). beta-Amyloid-mediated vasoactivity and vascular endothelial damage. *Nature* 380, 168–171.

Tian, G. F., Azmi, H., Takano, T., Xu, Q., Peng, W., Lin, J., et al. (2005). An astrocytic basis of epilepsy. *Nat. Med.* 11, 973–981.

Tong, G., and Jahn, C. E. (1994). Block of glutamate transporters potentiates postsynaptic excitation. *Neuron* 13, 1195–1203.

Tsacopoulos, M., and Magistretti, P. J. (1996). Metabolic coupling between glia and neurons. *J. Neurosci.* 16, 877–885.

Udenos, I. T., Jiang, H., Hercule, H. C., and Oyekan, A. O. (2003). Nitric oxide–epinephrine interactions and arachidonate-induced dilatation of rat renal microvessels. *Am. J. Physiol. Heart Circ. Physiol.* 285, H2014–H2023.

Uhlhaas, P. J., and Singer, W. (2006). Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. *Neuron* 52, 155–168.

Vannucci, S. J., Maher, F., and Simpson, I. A. (1997). Glucose transporter proteins in brain: delivery of glucose to neurons and glia. *Glia* 21, 2–21.

Ventura, R., and Harris, K. M. (1999). Three-dimensional relationships between hippocampal synapses and astrocytes. *J. Neurosci.* 19, 6897–6906.

Voloboueva, L. A., Suh, S. W., Swanson, R. A., and Gifford, R. G. (2007). Inhibition of mitochondrial function in astrocytes: implications for neuronal injury. *J. Neurochem.* 102, 1383–1394.

Voutouinis-Porche, B., Bonvento, G., Tanaka, K., Steiner, P., Welker, E., Chatton, J. Y., et al. (2003). Glial glutamate transporters mediate a functional metabolic crosstalk between neurons and astrocytes in the mouse developing cortex. *Neuron* 37, 273–286.

Waggepersten, H. S., Qu, H., Schousboe, A., and Sonnewald, U. (2001). Elucidation of the quantitative significance of pyruvate carboxylation in cultured cerebral neurons and astrocytes. *J. Neurosci. Res.* 66, 763–770.

Walraff, A., Kohling, R., Heinemann, U., Theis, M., Willecke, K., and Steinhauser, C. (2006). The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. *J. Neurosci.* 26, 5438–5447.

Walz, W., and Mukerji, S. (1988). Lactate release from cultured astrocytes and neurons: a comparison. *Glia* 1, 366–370.

Walz, W., and Muerkerji, S. (1990). Simulation of aspects of ischemia in cell culture: changes in lactate compartmentation. *Glia* 3, 522–528.

Warkentin, S., and Passant, U. (1997). Functional imaging of the frontal lobes in organic dementia. Regional cerebral blood flow findings in normals, in patients with frontotemporal dementia and in patients with Alzheimer’s disease, performing a word fluency test. *Dement. Geriatr. Cogn. Disord.* 8, 105–109.

Watase, K., Hashimoto, K., Kano, M., Yamada, K., Watanabe, M., Inoue, Y., et al. (1998). Motor coordination and increased susceptibility to cerebellar injury in GLAST mutant mice. *Eur. J. Neurosci.* 10, 976–988.

Wender, R., Brown, A. M., Fern, R., Swanson, R. A., Farrell, K., and Ransom, B. R. (2000). Astrocytic glycogen influences axon function and survival during glucose deprivation in central white matter. *J. Neurosci.* 20, 6804–6810.

Wilhelmus, M. M., Otte-Holler, L., Van Triel, J. J., Veerhuis, R., Maat-Schieman, M. L., Bu, G., et al. (2007). Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. *Am. J. Pathol.* 171, 1989–1999.

Wolff, J. R., Stuke, K., Misler, M., Tytko, H., Schwarz, P., Rohlmann, A., et al. (1998). Autocellular coupling by gap junctions in cultured astrocytes: a new view on cellular autoregulation during process formation. *Glia* 24, 121–140.

Wu, L., Cao, K., Lu, Y., and Wang, R. (2002). Different mechanisms underlying the stimulation of K(Ca) channels by nitric oxide and carbon monoxide. *J. Clin. Invest.* 110, 691–700.

Wyse, M. T., Jolivet, R., Buck, A., Magistretti, P. J., and Weber, B. (2011). In vivo evidence for lactate as a neuronal energy source. *J. Neurosci.* 31, 7477–7485.

Xu, Q., Tcheranova, D., Basuroy, S., Parfenova, H., Jaggar, J. H., and Leffler, C. W. (2011). Glutamate-induced calcium signals stimulate CO production in piglet astrocytes. *Am. J. Physiol. Heart Circ. Physiol.* 301, H1428–H1433.

Xi, Q., Umstot, E., Zhao, G., Narayanan, D., Leffler, C. W., and Jaggar, J. H. (2010). Glutamate regulates Ca2+ signals in smooth muscle cells of newborn piglet
brain slice arterioles through astrocyte- and heme oxygenase-dependent mechanisms. *Am. J. Physiol. Heart Circ. Physiol.* 298, H562–H569.

Ye, Z. C., Wyeth, M. S., Baltan-Tekkok, S., and Ransom, B. R. (2003). Functional hemichannels in astrocytes: a novel mechanism of glutamate release. *J. Neurosci.* 23, 3588–3596.

Yu, A. C., Drejer, J., Hertz, L., and Schousboe, A. (1983). Pyruvate carboxylase activity in primary cultures of astrocytes and neurons. *J. Neurochem.* 41, 1484–1487.

Zhang, W., Koerner, I. P., Noppens, R., Grafe, M., Tsai, H. J., Morisseau, C., et al. (2007). Soluble epoxide hydrolase: a novel therapeutic target in stroke. *J. Cereb. Blood Flow Metab.* 27, 1931–1940.

Zhang, W., Otsuka, T., Sugo, N., Ardeshiri, A., Alhadid, Y. K., Iliff, J. J., et al. (2008). Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. *Stroke* 39, 2073–2078.

Zhang, Y., Pertens, E., and Janssen, L. J. (2005). 8-isoprostaglandin E(2) activates Ca(2+)-dependent K(+) current via cyclic AMP signaling pathway in murine renal artery. *Eur. J. Pharmacol.* 520, 22–28.

Zonta, M., Angulo, M. C., Gobbo, S., Rosengarten, B., Hossmann, K. A., Pozzan, T., et al. (2003). Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. *Nat. Neurosci.* 6, 43–50.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.